1 COVID-19 mitigation behaviors and policies limited SARS-CoV-2 transmission in the United States from September
2 2020 through November 2021. ²2020 through November 2021.

3

4 **Authors**
5 Velma K.
6 Matthew
7 Velma K. Lopez, "Sarah Kada," Pragati V. Prasad,"
Matthew Biggerstaff, ² Michael A. Johansson ¹
Affiliations 5 Velma K. Lopez, ' Sarah Kada, ' Pragati V. Prasad, ' Taylor Chin, ' Betsy L. Cadwell, ' Jessica M. Healy, ' Rachel B. Slayton, '
6 Matthew Biggerstaff, ² Michael A. Johansson ¹
7

- 6 Matthew Biggerstaff, ² Michael A. Johansson ¹
7
8 **Affiliations** 1 National Center for Emerging and 2 8 **Affiliations**

¹ National Center for Emerging and Zoonotic Infe

¹⁰ Centers for Disease Control and Prevention (CDC).

² National Center for Immunization and Respirator

³ Global Health Center. Division Global
- ² National Center for Immunization and Respiratory Diseases, Influenza Division, CDC.
³ Global Health Center, Division Global Health Protection, CDC.
⁴ NCEZID, Division of Healthcare Quality Promotion, CDC.
- Centers for Disease Control and Prevention (CDC).

² National Center for Immunization and Respirator

³ Global Health Center, Division Global Health Prot

⁴ NCEZID, Division of Healthcare Quality Promotion ² National Center for Immunization and Respiratory Diseases, Influenza Division, CDC.

³ Global Health Center, Division Global Health Protection, CDC.

⁴ NCEZID, Division of Healthcare Quality Promotion, CDC.

14
- ⁹ Global Health Center, Division Global Health Protection, CDC.

⁴ NCEZID, Division of Healthcare Quality Promotion, CDC.

¹⁴ * Corresponding author: oko8@cdc.gov ⁴13
- 15

7

*Corresponding author: oko8@cdc.gov $\frac{14}{15}$

16
17

Abstract
United States' jurisdictions implemented varied policies to slow SARS-CoV-2 transmission. Understanding patterns of
these policies alongside individual's behaviors can inform effective outbreak response. To do so, 17 **Abstract**
18 United St
19 these pol
20 varying re 18 these policies alongside individual's behaviors can inform effective outbreak response. To do so, we estimated the time-
varying reproduction number (R_t), a weekly measure of real-time transmission using US COVID-19 cas 19 behaviors, variants, immunity, and social vulnerability indicators using two multi-level regression models. First, we fit a 20 2020-November 2021. We then assessed the association between R_t and policies, personal COVID-19 mitigation
behaviors, variants, immunity, and social vulnerability indicators using two multi-level regression models. Firs 2020-November 2021. We then assessed the association between R_t and policies, personal COVID-19 mitigation
22 behaviors, variants, immunity, and social vulnerability indicators using two multi-level regression models. F 22 model with state-level policy stringency according to the Oxford Stringency Index, a composite indicator reflecting the
strictness of COVID-19 policies and strength of pandemic-related communication. Our second model inclu 23 model with state-level policies and strength of pandemic-related communication. Our second model included a subset
of specific policies. We found that personal mitigation behaviors and vaccination were more strongly associ 24 strictive policies. We found that personal mitigation behaviors and vaccination were more strongly associated with
decreased transmission than policies. Importantly, transmission was reduced not by a single measure, but by 25 decreased transmission than policies. Importantly, transmission was reduced not by a single measure, but by various
layered measures. These results underscore the need for policy, behavior change, and risk communication in 26 layered measures. These results underscore the need for policy, behavior change, and risk communication integration to
reduce virus transmission during epidemics. 27 layered measures. These results understand measures in policies in policy, and risk communication integration in
reduce virus transmission during epidemics. 28 reduce virus transmission during epidemics.

29
30

³¹

³⁰

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

³² MAIN TEXT

³³

Introduction

35

ノイ 36 the average number of cases infected by each infectious person in a fully susceptible population, indicated that the virus
was more transmissible than influenza (1) with a median R₀ estimate of 2.79 (2). With limited kn 37 was more transmissible than influenza (1) with a median R_0 estimate of 2.79 (2). With limited knowledge about
transmission dynamics and no vaccines to mitigate viral spread, governments began to implement travel restri 38 transmission dynamics and no vaccines to mitigate viral spread, governments began to implement travel restrictions and
stay-at-home orders to reduce contact between individuals and opportunities for transmission. These non 39 transmission and orders to reduce contact between individuals and opportunities for transmission. These non-
pharmaceutical intervention (NPI) policies rapidly evolved and eventually encompassed a spatially and temporally
 40 cancellation or large events, limiting the size or social gatherings, shutting down workplaces and schools, or mandating 41 pharmaceutical intervention (NPI) political intervents of the state in the state intervents of the state inter
Cancellation of large events, limiting the size of social gatherings, shutting down workplaces and schools, or 42 cancellation of large events, limiting the size of social gatherings, shutting down workplaces and schools, or mandating
the use of masks in public spaces.
-43 the use of masks in public spaces.
Published evidence showed that NPI policies, such as stay-at-home orders and closure of public facilities, slowed SARS-44

45

CoV-2 spread throughout the world during the early phase of the pandemic $(3-5)$. Extensive evidence has also
accumulated about the effectiveness of other specific NPI policies, such as limiting the size of gatherings and F
c 46 $\frac{1}{2}$ published that NPI policies, and their compinations being more effective than stay-at-home orders (3, 5). Changes in 47 accumulated about the effectiveness of other specific NPI policies, such as limiting the size of gatherings and closing
schools or universities, and their combinations being more effective than stay-at-home orders (3, 5). 48 acchools or universities, and their combinations being more effective than stay-at-home orders (3, 5). Changes in
behavior that were not explicitly linked to policies, as well as climatic and sociodemographic factors, also 49 behavior that were not explicitly linked to policies, as well as climatic and sociodemographic factors, also appeared to
affect transmission dynamics. For example, social structure dramatically influences SARS-CoV-2 transm 50 affect transmission dynamics. For example, social structure dramatically influences SARS-CoV-2 transmission dynamics
by affecting how people interact. Within the United States (US), it became evident that physical distanci 51 by affecting how people interact. Within the United States (US), it became evident that physical distancing by staying
home from work was a policy option available to more wealthy and White individuals rather than frontlin 52 home from work was a policy option available to more wealthy and White individuals rather than frontline, essential
worker populations (6), who are more likely to have a lower socioeconomic status and belong to racial min 53 worker populations (6), who are more likely to have a lower socioeconomic status and belong to racial minoritized
communities (7, 8). Additionally, SARS-CoV-2 testing sites may have been disproportionately available in ar 54 worker populations (6), who are more likely to have a lower socioeconomic status and belong to racial minoritized
communities (7, 8). Additionally, SARS-CoV-2 testing sites may have been disproportionately available in are 55 communities (7, 8). Additionally, SARS-COV-2 testing sites may have been disproportionately available in areas that had a
greater proportion of White residents (9–11). In other words, the opportunity to know one's infectio 56 greater proportion of white residents (9–11). In other words, the opportunity to know one's infection status and limit
interactions with others, if necessary, was only available to a privileged subset of the population. Mo 57 factors added further complexity to these dynamics. For example, the literature suggests that SARS-CoV-2 transmission
decreases as temperature and specific humidity increases (12); potentially by weakening the viral envelo 58 decreases as temperature and specific humidity increases (12); potentially by weakening the viral envelope (13) and
impacting when people spend time indoors and under conditions more favorable to viral transmission. Additi 59 decreases as temperature and specific humany increases (12); potentially by weakening the viral envelope (13) and
impacting when people spend time indoors and under conditions more favorable to viral transmission. Addition 60 impacting when people open time time indoors and undertoon include the conditions of the pandemic progressed, the role of post-infection and post-vaccination immunity and the role of viral evolution also
became apparent. W 61 became apparent. Whether COVID-19 mitigation policies effectively reduced transmission thus requires an assessment within the broader context of behavior, social factors, and weather conditions. 62 within the broader context of behavior, social factors, and weather conditions.
The US COVID-19 epidemic provides an opportunity to assess the contribution of many of these factors to SARS-CoV-2 63

within the US COVID-19 epidemic provides an opportunity to assess the contributior.
The US COVID-19 context of behaviors, were heterogeneously $\frac{1}{j}$ 65 The US COVID-19 mitigation policies were heterogeneously implemented over time and across
jurisdictions (14). Overall, 55 million cases and over 820,000 deaths were reported in the United States by December 31,
2021 (15), 66 transmittions (14). Overall, 55 million cases and over 820,000 deaths were reported in the United States by December 31,
2021 (15), patterned by existing demographics and health disparities within each jurisdiction. Given 67 jurisdictions (14). Overall, 55 million cases and over 820,000 deaths were reported in the onlied states by Beethiber 31,
2021 (15), patterned by existing demographics and health disparities within each jurisdiction. Given 68 case and death patterns and the overall success of NPI policies in other countries, we seek to understand spatial and
temporal impact of COVID-19 mitigation policies on US SARS-CoV-2 transmission. We do so by first estimat 69 temporal impact of COVID-19 mitigation policies on US SARS-CoV-2 transmission. We do so by first estimating the time-70 indirectly affect or modify community transmission, including personal COVID-19 mitigation behaviors, the circulation of 71 the ecological associations between R_t and time-varying mitigation policies, explicitly adjusting for factors that directly or 72 the ecological associations between R_t and time-varying mitigation policies, explicitly adjusting for factors that directly or
73 indirectly affect or modify community transmission, including personal COVID-19 mitigat 73 key SARS-CoV-2 variants, weather data, indicators of immunity, and COVID-19 vulnerability indicators.
Results 74 key SARS-Cov-2 variants, weather data, indicators of immunity, and COVID-19 vulnerability indicators.
Results
-

⁷⁵

64

77

78 Between September 2020 and November 2021, R_t estimates exhibited spatiotemporal variability across the United
79 States (Figure 1). All jurisdictions experienced sustained increases in transmission ($R_t > 1$) in late |
|
|
| States (Figure 1). All jurisdictions experienced sustained increases in transmission ($R_t > 1$) in late 2020, followed by a States (Figure 1). All jurisdictions experienced sustained increases in transmission (R_t > 1) in late 2020, followed by a
80 period of fluctuations until the Delta wave in the summer of 2021, when many had their highest beriod of fluctuations until the Delta wave in the summer of 2021, when many had their highest R_t estimates. Despite
in 80 estimates. Despite by the 80 estimates of 2021, when many had their highest R_t estimates. Desp

some consistency in trends, our results reveal that R_t dynamics differed substantially between jurisdictions, such as the
s2 timing and rate of the transmission increases in late 2020 during the Alpha wave. The lowest m this period was for Vermont in May 2021 ($R_z=0.66$) and the highest value was for the District of Columbia (DC) in 83 84

85

this period was for Vermont in May 2022 (R_t=0.66) and the highest value was for the District of Columbia (DC) in
Stay-at-home orders, gathering limitations, cancellation of public events, and mask mandates all exhibited ر
Stay-at-home orders, ga
spatiotemporal variability $\frac{1}{2}$ 86 spatiotemporal variability (Figure 1) and moderate correlation (maximum: 0.47, Supplemental Figure 1B). Hawaii,
Illinois, Rhode Island, and Virginia implemented all four of these policies at least once, while other jurisdi 87 spational variability (Figure 1) and moderation constantine (manutation 1999) deptendent or part 1998 1199, Manah)
Illinois, Rhode Island, and Virginia implemented all four of these policies at least once, while other juri 88 Illinois, Alaska, Florida, Iowa, Missouri, Montana, Oklahoma, and South Dakota, did not implement any of them. Overall,
Stringency of mitigation policies dipped slightly in October 2020 and decreased substantially between 89 stringency of mitigation policies dipped slightly in October 2020 and decreased substantially between March and June
2021 (Figure 2A). Variation in policy stringency across jurisdictions persisted throughout the study peri 90 2021 (Figure 2A). Variation in policy stringency across jurisdictions persisted throughout the study period, with the
lowest median value in South Dakota (0.09; range: 0.06 to 0.21) and the highest median value in Hawaii (91 lowest median value in South Dakota (0.09; range: 0.06 to 0.21) and the highest median value in Hawaii (0.66; range:
0.44 to 0.76). 92 93

94

107

13

Personal COVID-19 mitigation behaviors also varied over time and space (Figure 2A). Reductions in national airline travel and individual mobility showed similar patterns over time, though individual mobility also varied by jurisdiction.
Reductions in both were substantial and relatively static until March 2021, at which point airline travel a F
F
F 95 and individual mobility showed similar patterns over time, though individual mobility also varied by jurisdiction
Reductions in both were substantial and relatively static until March 2021, at which point airline travel an 96 Reductions in both were substantial and relatively static until March 2021, at which point airline travel and mobility
began to return closer to pre-pandemic levels. Across jurisdictions and time periods, self-reported mas 97 Reductions in the two metals in both were substantial and relatively and time periods, self-reported mask use and gathering attendance among survey respondents were highly negatively correlated (-0.83, Supplemental Figure 98 began to return closer to pre-pandemic levels. And they are the protected (-0.83, Supplemental Figure 2),
indicating that both are likely indicators of personal risk reduction behaviors. Because of the high correlation, we 99 indicating that both are likely indicators of personal risk reduction behaviors. Because of the high correlation, we
focused on a single variable, self-reported mask use, as an indicator of personal protection measures for 100 focused on a single variable, self-reported mask use, as an indicator of personal protection measures for further
analyses. Reported mask use was also positively correlated with local mobility (Supplemental Figure 1A, R² 101 analyses. Reported mask use was also positively correlated with local mobility (Supplemental Figure 1A, R^2 value of 0.68)
but had distinct patterns. For example, the weekly proportion of respondents that self-reported 103 remained above 75% in most jurisdictions until May 2021, when it declined sharply. In August 2021, all three mitigation
behavior indicators increased, with new reductions in national airline travel and local mobility, as w 104 remained above 75% in most jurisdictions in mathematic process in the standard sharply. In August 2021, all three mingdivents
behavior indicators increased, with new reductions in national airline travel and local mobility 105 behavior indicators increased, with new reductions in national annual and local mobility, as well as increased
The increased personal mitigation behaviors in August 2021 coincided with the rapid increase in prevalence of t 106

report
The increased personal mitigati
variant (Figure 2A, Supplement ן
|
| 108 variant (Figure 2A, Supplemental Figure 1A). Expansion of the Alpha variant in early 2021 was generally slower, more heterogeneous, and not correlated with increased mitigation behavior. In addition to potential direct eff 109 heterogeneous, and not correlated with increased mitigation behavior. In addition to potential direct effects on 110 transmission, increased temperature (highly correlated with absolute humidity, Supplemental Figure 3) was associated 111 12

with decreased personal mitigation behaviors and increased rates of vaccination (Supplemental Figure 1).
There was high heterogeneity in jurisdictional SARS-CoV-2 seroprevalence throughout the analysis period. By the end o with decreases behaviors of the crease of the crease.
There was high heterogeneity in jurisdictional SARS-CoV-2 seroprevalence throughout the analysis period
November 2022, seroprevalence ranged from 0.10 in Vermont to 0.4 ך
ו 114 There was high heterogeneity in jurisdictional SARS-Cover-2 in Figure 2022, seroprevalence ranged from 0.10 in Vermont to 0.46 in Wyoming (Figure 2A). The proportion of the population that was fully vaccinated with an init 15 November 2022, servey the range from initial vaccine series increased across all jurisdictions beginning with the
Vaccination distribution in early 2021 and ranged from 0.47 (Alabama) to 0.75 (Vermont) at the end of Novemb 16 vaccination distribution in early 2021 and ranged from 0.47 (Alabama) to 0.75 (Vermont) at the end of November 2021.
Increased seroprevalence and vaccination coverage were correlated with each other (0.69, Supplemental Fig 117 Increased seroprevalence and vaccination coverage were correlated with each other (0.69, Supplemental Figure 1A), 118 with long-term decreases in the mitigation behavior indicators (-0.48 to -0.98), and with the prevalence of the Delta 119 120

21

with long-term decreases in the mitigation behavior indicators (-0.48 to -0.99), and with the prevalence of the
Variant (0.52 and 0.83, respectively).
Community COVID-19 Vulnerability Index (CCVI) indicators showed high he variant (1022 and 103) respectively).
Community COVID-19 Vulnerability
(Supplemental Figure 5A) and some $\frac{1}{2}$ 22 (Supplemental Figure 5A) and some correlation with temperature, vaccine coverage, and personal mitigation practices
(Supplemental Figure 5B). Average vulnerability across the five indicators showed higher vulnerability in 123 (Supplemental Figure 5B). Average vulnerability across the five indicators showed higher vulnerability in southern
jurisdictions (Figure 2B), with the highest average vulnerability in Texas (0.80), Arizona and California (124 (Suppremental Figure 2B), with the highest average vulnerability in Texas (0.80), Arizona and California (0.72,
respectively). Vermont had the lowest average vulnerability (0.15), followed by New Hampshire (0.22) and Monta 125 respectively). Vermont had the lowest average vulnerability (0.15), followed by New Hampshire (0.22) and Montana
(0.27). 126 respectively). Vermont had the lowest average vulnerability (0.27), for \mathcal{N} and \mathcal{N} and Montanability (0.22) and Montanability (0.222) and Montanability (0.222) and Montanability (0.222) and Montanability (0.222 127 $\overline{}$

129 R_t on the logarithmic scale over time in all jurisdictions: the Oxford Stringency Index (OSI) Model using OSI as the only
policy indicator and the Individual Policy Model, using four specific policies: cancellation of p 131 policy individual and the Individual Policy Model, using Four specific policies in Equivement Policy Controllin
alternative spatiotemporal model structures and found that a model with independent random effects for time an 132 alternative spatiotemporal model structures and found that a model with independent random effects for time and
state provided the best fit to the data (see Supplement 8). We also adjusted for other factors described abov 133 state provided the best fit to the data (see Supplement 8). We also adjusted for other factors described above that 134 potentially contribute to R_t: individual behavior, the prevalence of specific variants, immunity, weather, and community
risk factors (i.e., the CCVI indicators). Fixed effect intercepts for both models indicate average 135 The state of the CCVI indicators). Fixed effect intercepts for both models indicate average expected R_t values well
above 1.0 without any mitigation behaviors or policies. With moderate values for CCVI indicators (0.5 e 137 temperature (12°C), estimated R_t in the absence of mitigation was 2.6 for the OSI Model (95% Credible Interval [CI]: 1.9-
3.5) and 2.5 (95% CI 1.9-3.4) for the policy model. temperature (12°C), estimated R_t in the absence of mitigation was 2.6 for the OSI Model (95% Credible Interval [CI]: 1.9-
3.5) and 2.5 (95% CI 1.9-3.4) for the policy model.
41 While some policies and behavior indicator 139

140

 $\begin{aligned} \text{While some policies and behavior indicators we} \\ \text{reduced mobility (R}^2=0.53, \text{ Supplemental Figure} \end{aligned}$ $\frac{1}{c}$ 141 reduced mobility (R^2 = 0.53, Supplemental Figure 1), we included both types of covariates in the regression models to assess the relative strength of their associations with R_t . Overall stringency, some of the specif assess the relative strength of their associations with R_t . Overall stringency, some of the specific individual policies, and
each of the behavioral components were associated with decreased R_t (Figure 3). Implementat assess the relative strength of their associations with R_t. Overall stringency, some of the specific individual policies, and
each of the behavioral components were associated with decreased R_t (Figure 3). Implementat each of the behavioral components were associated with decreased R_t (Figure 3). Implementation of half of the strictest
policies (i.e., OSI at 50%) relative to no policies (OSI at 0%) was estimated to decrease R_t by 6 policies (i.e., OSI at 50%) relative to no policies (OSI at 0%) was estimated to decrease R_t by 6.7% (95% CI: 5.1- 8.3%). In
the model with individual policies, cancellation of public events decreased R_t by 2.6% (95% que model with model of the model with the model with models with models. Mask mandates had a
the mean estimate corresponding to a 0.7% reduction in R_t but did not reach statistical significance (95% CI: -1.5-0.2%).
Str 147 mean estimate corresponding to a 0.7% reduction in R_t but did not reach statistical significance (95% CI: -1.5-0.2%). mean estimate corresponding to a 0.7% reduction in R_t but did not reach statistical significance (95% CI: -1.5-0.2%).

Strong associations were also observed for personal mitigation behaviors in both models. For the OSI Strong associations were also observed for personal mitigation behaviors in both models. For the OSI Model, R_t was

estimated to decrease by 22% (95% CI: 18%-26%) if there were a 50% reduction in national airline travel 50 2.4-3.3%) if local movement to recreation and retail locations decreased by 10%, and 14% (95% CI: 12-15%) if self-
reported mask use reached 50%. Sensitivity analysis showed consistent estimates for policy impacts even whe 151 52 153

reported maturals used is consistent for a summing analysis showed consistent estimates for policy impacts of t
In both models, a 50% increase in the proportion of Alpha variant in circulation had a likely positive but not In both models, a 50% increase in the proportion of μ association with R_t (95% Cl: -0.20-0.10%, OSI Model) 154 $\frac{1}{c}$ 155 association with R_t (95% CI: -0.20-0.10%, OSI Model), while a 50% increase in the proportion of Delta among current variants was associated with a 0.1% (95% CI: 0.01-0.02%, OSI Model) increase (Figure 3). Seroprevalence association with R_t (95% CI: -0.20-0.10%, OSI Model), while a 50% increase in the proportion of Delta among current
variants was associated with a 0.1% (95% CI: 0.01-0.02%, OSI Model) increase (Figure 3). Seroprevalence 157 were both associated with reduced R_t in each of the models, a 30% (95% Cl: 28-32%, OSI Model) and 22% (95% Cl: 18-
26%, OSI Model) estimated reduction if half of the population had been previously infected or fully vacc 59 respectively. Increased temperature was associated with a 4.0% (95% Cl: 3.0-5.0%, OSI Model) decrease in R_t per 10°C
increase in mean weekly temperature. Among sociodemographic factors, we found that greater population 161 greater racial and ethnic diversity were associated with increased R_t in both models. Coefficients were similar in
direction for both models, with or without informative priors (see Supplement 6), and with alternative e greater racial and ethnic diversity were associated with increased R_t in both models. Coefficients were similar in
63 direction for both models, with or without informative priors (see Supplement 6), and with alternativ direction for both models, with or without informative priors (see Supplement 6), and with alternative estimates of R_t (see Supplement 9), minor differences in magnitude were observed in our sensitivity analyses (Supple 164 165

(see Supplemental Correction 9), and the Supplemental Correction 3), we set
We estimated the proportional reduction associated with each time-varying component individually and con
Leach jurisdiction and nationally over ti しらく 166 each jurisdiction and nationally over time using the OSI Model estimates (Figure 4, Figure 5, and Supplemental Figure 7).
Over the entire study period, personal mitigation behaviors were associated with the largest proport 167 reductions in all jurisdictions before vaccine implementation and remained an important or leading contributor to 168 The entire study period, performant mingular permittent and terminal minimization proportion contributor to
reduction thereafter (median combined reduction over time across locations: 44%, range: 10-62%) (Figure 5). Immuni 69 reduction thereafter (median combined reduction over time across locations: 44%, range: 10-62%) (Figure 5). Immunity
was the second most important contributor overall and of growing importance as more people were infected 170 was the second most important contributor overall and of growing importance as more people were infected and
vaccination coverage increased. These patterns, however, were starkly different across the United States (Figure 171 vaccination coverage increased. These patterns, however, were starkly different across the United States (Figure 4 and
Supplemental Figure 7). For example, in November 2021 many jurisdictions had higher estimated reduction 172 Supplemental Figure 7). For example, in November 2021 many jurisdictions had higher estimated reductions associated
with previous infections than vaccination (e.g., Wyoming). Meanwhile other jurisdictions with lower seropo 173 Suppremental Figure 1, 1993. The example, in November 2021 many jurisdictions many is community forward to write
with previous infections than vaccination (e.g., Wyoming). Meanwhile other jurisdictions with lower seroposit 174 more vaccinations had higher estimated reductions associated with vaccination (e.g., Vermont). At the end of the study
period, SARS-CoV-2 seroprevalence and vaccination were associated with a wide range of reductions acros 175 period, SARS-CoV-2 seroprevalence and vaccination were associated with a wide range of reductions across jurisdictions 176 period, SARS-CoV-2 seroprevalence and vaccination were associated with a wide range of reductions across jurisdictions

177 (8-35% and 24-36%, respectively). Policies and weather were also associated with changes in transmission but with less
overall estimated magnitude than the effects of behavior and immunity.
Discussion 178

79
80

overall estimated magnitude than the effects of behavior and immunity.

181

Deciphering SARS-CoV-2 transmission drivers throughout the pandemic can inform development of policies and interventions for mitigation of respiratory pathogens. Our analysis integrates spatial and temporal patterns of pot I
i
t 82 interventions for mitigation of respiratory pathogens. Our analysis integrates spatial and temporal patterns of potential
transmission determinants to assess associations between those determinants and SARS-CoV-2 transmiss 183 findings presented here are derived from large scale data and are statistically supported, but they cannot establish 184 Tindings presented here are derived from large scale data and are statistically supported, but they cannot establish
causality due to the limitations of each dataset and the many known and unknown potential confounders. No 185 causality due to the limitations of each dataset and the many known and unknown potential confounders. Nonetheless,
two important insights for mitigation strategies were elucidated. First, while both general and specific p 186 two important insights for mitigation strategies were elucidated. First, while both general and specific policies and
behavior were associated with reduced SARS-CoV-2 transmission, masking wear and reduced airline travel w 187 behavior were associated with reduced SARS-CoV-2 transmission, masking wear and reduced airline travel were
associated with greater transmission reductions. Second, throughout the study period multiple factors contributed 188 behavior were associated with greater transmission reductions. Second, throughout the study period multiple factors contributed to limiting transmission; personal mitigation behavior had large impacts early on while the im 89 limiting transmission; personal mitigation behavior had large impacts early on while the importance of previous infection and vaccination increased as population-level immunity increased over time. As these effects are con 190 infection and vaccination increased as population-level immunity increased over time. As these effects are considered
multiplicative in the model, the findings imply that combinations of behavioral mitigation were critical 191 multiplicative in the model, the findings imply that combinations of behavioral mitigation were critical to limiting
transmission throughout the study period.
-192 193

194

transmission throughout the study period.
Early COVID-19 mitigation strategies in US jurisdictions focused on physical distancing (e.g., stay at home orders, transmission throughout the study period.
Early COVID-19 mitigation strategies in l
cancelation of public events, restricting l
C
C 195 cancelation of public events, restricting gathering sizes) and masking policies. Our estimates suggest that physical
distancing policies reduced SARS-CoV-2 transmission, with an estimated mean reduction of 1-3% for individ 196 distancing policies reduced SARS-CoV-2 transmission, with an estimated mean reduction of 1-3% for individual policies
and an estimated total reduction of approximately 6% if sets of policies tracked by the OSI reach 50%. 197 and an estimated total reduction of approximately 6% if sets of policies tracked by the OSI reach 50%. These reductions 198 are in line with other, short term, national-level assessments of NPI policies and showed reductions in COVID-19 cases
(16–19), transmission (20–22), and deaths (17); there was some reduction in effectiveness for policies 199 (16–19), transmission (20–22), and deaths (17); there was some reduction in effectiveness for policies with longer

durations (17). In contrast to our null results for masking policies, jurisdiction-specific studies show 201 durations (17). In contrast to our null results for masking policies, jurisdiction-specific studies show short-term
effectiveness of mask mandates at reducing cases (23) and hospitalization growth rates (24). Importantly, 02 effectiveness of mask mandates at reducing cases (23) and hospitalization growth rates (24). Importantly, most of these
early evaluations focused on the period in which the NPIs were in effect and did not assess long-term 203 when the NPI was not implemented, as was done here. There is some evidence of limited prolonged reduction in COVID-
19 outcomes when NPI policies were lifted (25), with more socially disadvantaged communities experiencing 04 reductions in transmission was strong but accounted for only a modest overall reduction in transmission risk. This 05 19 outcomes when NPI policies were lifted (25), with more socially disadvantaged communities experiencing greater
rebounds in COVID-19 burden than other communities (26). Overall, the association between individual policie 206 reductions in COVID-19 burden than other communities (20). Overall, the association between individual polices and
reductions in transmission was strong but accounted for only a modest overall reduction in transmission ris 07 finding is due to the model's inclusion of related factors like NPI policy implementation stringency and proxies for
adherence to the policies via personal mitigation behaviors. 208 09

210

adherence to the policies via personal mitigation behaviors.
The relationships underlying policy implementation and behavior are complex and reflect personal characteristics, community characteristics, and social structure. Like others, we found indicators of behavior such as local mobility, ן
ג
ו 211 Community characteristics, and social structure. Like others, we found indicators of behavior such as local mobility, national airline travel, and self-reported mask use to be associated with significant reductions in R_t 212 national airline travel, and self-reported mask use to be associated with significant reductions in R_t although not
necessarily temporally aligned with the corresponding policies (27). For example, analysis of early mob national airline travel, and self-reported mask use to be associated with significant reductions in R_t although not
14 are necessarily temporally aligned with the corresponding policies (27). For example, analysis of ea 214 necessarily temporally aligned with the corresponding policies (27). For example, analysis of early mobility data showed
that movement patterns in the United States changed drastically even before the implementation of mos 215 that move mention patterns in the United States changes and the include the implementation. It is plausible that
broad agreement within the physical distancing policies early in the pandemic (30) influenced personal choice 216 distancing policies (28), with continued reductions in movement after policies were in place (29). It is plausible that
broad agreement within the physical distancing policies early in the pandemic (30) influenced persona 217 broad agreement within the physical distancing policies early in the pandemic (30) inhacticed personal choices to stay
home. Similarly, mask use increased, and local mobility decreased rapidly as the Delta wave grew even t 218 recommendations stated that vaccinated individuals could resume pre-pandemic activities without wearing a mask,
once again, indicating a behavioral response that was independent of policy. Conversely, one example of tempor 219 once again, indicating a behavioral response that was independent of policy. Conversely, one example of temporal
alignment between policy and behavior was immediately following the May 2021 guidance update when there was a 220 once again, indicating a behavior to performal response that was performed to policy. The entirety of temporal
alignment between policy and behavior was immediately following the May 2021 guidance update when there was a
t 221 rapid decrease in reported mask use and increases in local mobility, likely an effect of individuals returning to activities that had previously stopped due to the pandemic. 22 rapid decreases in represent mask use and increases in the three controls in the individuals returning to a control model model model model model model with the set of individuals returning to a control of individuals retu 223 that had previously stopped due to the pandemic.

25 Prior to the Delta wave, vaccination rates across the United States were steadily rising, with varying geospatial, socioeconomic, and race and ethnic patterns of vaccination coverage $(31, 32)$. Many jurisdictions had als 26 socioeconomic, and race and ethnic patterns of vaccination coverage (31, 32). Many jurisdictions had also experienced
substantial transmission in 2020 and early 2021, resulting in greater infection-acquired immunity in the 227 while we did not adjust for waning immunity (33), changing vaccine effectiveness with time from vaccination and with
the appearance of new variants (33, 34), we found associations of both infection-acquired immunity and va 228 While we did not adjust for wannig immunity (33), changing vaccine effectiveness with time from vaccination and with
the appearance of new variants (33, 34), we found associations of both infection-acquired immunity and va 229 the appearance of new variants (33, 34), we found associations of both infection-acquired immunity and vaccination
with decreased transmission. It is plausible that if we adjusted our model estimates for waning immunity, t 230 the immunity-related associations would be attenuated. In most states, the relative impact of either infection-acquired
immunity or vaccination was estimated to be as high as the decreasing impact of behavior change by Nov 31 the immunity-relations was estimated to be as high as the decreasing impact of behavior change by November 2021,
when the impact of vaccination was estimated to be higher than the impact of infection-acquired immunity. The 32 immum, in the impact of vaccination was estimated to be higher than the impact of infection-acquired immunity. There were
also distinct differences across states, with some states showing comparable impact by late 2021 (e. 33 also distinct differences across states, with some states showing comparable impact by late 2021 (e.g., Alabama,
Arkansas) and others showing much higher impact from vaccination than infection-acquired immunity (e.g., Conn 234 Arkansas) and others showing much higher impact from vaccination than infection-acquired immunity (e.g., Connecticut,
Hawaii). Additionally, we did not adjust our model for COVID-19 testing, which may have a non-linear rel 35 Hawaii). Additionally, we did not adjust our model for COVID-19 testing, which may have a non-linear relationship with
seropositivity since testing availability and behaviors changed over time. 236 seropositivity since testing availability and behaviors changed over time.
Social structure drives transmission patterns for all pathogens and the US COVID-19 epidemic highlighted existing social 37

238

fault lines that influenced not only who in society was more likely to get infected, but also who was more likely to
benefit from mitigation measures (35, 36). Here, we accounted for multiple social vulnerability indicator ؟
f 39 fault lines that influenced not only who in society was more likely to get infected, but also who was more likely to
benefit from mitigation measures (35, 36). Here, we accounted for multiple social vulnerability indicator 240 benefit from mitigation measures (35, 36). Here, we accounted for multiple social vulnerability indicators and found
national-level evidence of higher transmission rates in states with higher population density and greater 241 benefit from imagenon measures (35, 36). Here, we accounted for multiple social vulnerability indicators and found
national-level evidence of higher transmission rates in states with higher population density and greater r 242 ethnic diversity. Our findings are in line with several results from county level analyses. For example, higher rates of SARS-CoV-2 transmission occurred in low-income and racial minoritized communities (37). Additionally, 243 SARS-CoV-2 transmission occurred in low-income and racial minoritized communities (37). Additionally, counties with 244 higher social vulnerability were more likely to become a COVID-19 burden hotspot (38), that is a geographic area with 245 higher social vulnerability were more likely to become a COVID-19 burden hotspot (38), that is a geographic area with
elevated disease incidence (39). Because structural racism is part of the intersectional factors compris 246 elevated disease incidence (39). Because structural racism is part of the intersectional factors comprising social
vulnerability, it is unsurprising that hotspots were common in US counties with a greater percentage of non 247 residents (40–42). These findings highlight the importance of incorporating social markers of risk in infectious disease transmission models (43). 248 249

residents (40–42). These findings highlight the importance of incorporating social markers of risk in infectious disease
transmission models (43).
Our findings are limited to associations and not causal relationships. Esta transmission models (43).
Our findings are limited to
and transmission is compl 250۲
ا 51 and transmission is complicated by a variety of risk factors, from the emergence of SARS-CoV-2 variants and changes in
human behavior to environmental conditions–all of which fluctuate over time and space. First, many of t 252 human behavior to environmental conditions–all of which fluctuate over time and space. First, many of the important
determinants of SARS-CoV-2 transmission are correlated and have complex interactions. To partially address 53 determinants of SARS-CoV-2 transmission are correlated and have complex interactions. To partially address this
limitation, we removed highly correlated variables that measured similar factors when possible. However, we di 54 limitation, we removed highly correlated variables that measured similar factors when possible. However, we did choose 55 to retain some highly correlated variables. For example, COVID-19 vaccination and the recovery of national airline travel
had a strong correlation (correlation coefficient: -0.94 between vaccination and travel reductions) 256 had a strong correlation (correlation coefficient: -0.94 between vaccination and travel reductions) largely driven by
increased travel in early 2021 which occurred at the same time as the expansion of vaccine availability 57 increased travel in early 2021 which occurred at the same time as the expansion of vaccine availability and uptake
Increased national travel likely has some direct relationship with vaccination due to increased willingness 258 increased national travel likely has some direct relationship with vaccination due to increased willingness or interest in
travel for vaccinated individuals; however, other factors, such as decreased case numbers, increase 59 Increased for vaccinated individuals; however, other factors, such as decreased case numbers, increased numbers of people
with infection-acquired immunity, or changing risk perceptions, likely also contributed. Second, we 260 with infection-acquired immunity, or changing risk perceptions, likely also contributed. Second, we applied a regression
framework, which assumes log-linear independence between covariates that does not account for the obs 61 framework, which assumes log-linear independence between covariates that does not account for the observed
correlation between variables. Overall, the potential causal pathways between the predictors and R_t are not indiv 262 for the prediction of the potential causal pathways between the predictors and R_t are not individually
identifiable at this scale. We encourage caution in interpretation of any single association general insight into SA 64 65 266

identifiable at this scale. We encourage caution in interpretation of any single association general insight into SARS-CoV-2
2 Related limitations apply for our
potentially important details of |
|
|
| 67 potentially important details of each policy. For example, we used state level policy indicators that may differ
substantially from policies implemented at a county or city level. Additionally, many different variations of 268 potentially from policies implemented at a county or city level. Additionally, many different variations of policies were
implemented (e.g., some jurisdictions required masks universally, whereas others only in certain loc 69 substantially from policies implemented at a county of the substantial many different control of policies implemented (e.g., some jurisdictions required masks universally, whereas others only in certain locations or where 270 physical distancing was not possible), even within jurisdictions, and those variations were not captured here. Instead, we
opted to use a limited set of policy classifications and assigned those to the entirety of each jur 271 opted to use a limited set of policy classifications and assigned those to the entirety of each jurisdiction. Use of the 272 opted to use a limited set of policy classifications and assigned those to the entirety of each jurisdiction. Use of the

composite policy indicator, the OSI, is a complementary approach to the same challenge but is also a necessary over-273 274

Our analysis found that diverse efforts had substantial associations with SARS-COV-2 transmission across the United
simplification of the diversity of policies inpremented.
Our analysis found that diverse efforts had substanti
States in 2020-2021. Ideally the wealth of data and $\frac{1}{2}$ 276 States in 2020-2021. Ideally the wealth of data and diversity of interventions in the United States could be used to develop specific recipes for control. However, that diversity and correlation between many contributing f 277 develop specific recipes for control. However, that diversity and correlation between many contributing factors makes 278 precise estimates of specific interventions and combinations of intervention infeasible. Here, we focused on an
ecological scale analysis of key types of strategies and found evidence that personal mitigation behaviors (e. 279 precise is a state analysis of key types of strategies and found evidence that personal mitigation behaviors (e.g., masking, physical distancing) were more strongly associated with decreased transmission than policies. Whi 80 ecological distancing) were more strongly associated with decreased transmission than policies. While most policies may
not be sufficient to control COVID-19 on their own, a combination of policies and communication effort 81 physical distance of surfact and the strongtheory and their and the strongly and ten support, and reinforce behavior change may be an essential pathway for control. The other most impactful intervention support, and reinfo 82 support, and reinforce behavior change may be an essential pathway for control. The other most impactful intervention
was vaccination, a nationwide intervention that was not available early on but became as important as be 83 was vaccination, a nationwide intervention that was not available early on but became as important as behavior
modification for controlling transmission in most jurisdictions by mid to late 2021 (29). Importantly, at all t 84 was intervention, a national transmission in most jurisdictions by mid to late 2021 (29). Importantly, at all time points, transmission was reduced not by a single measure, but by various layered measures indicating that n 85 modification was reduced not by a single measure, but by various layered measures indicating that no single measure is
likely to control SARS-CoV-2 on its own. Even with high rates of post-infection immunity or vaccination 286 likely to control SARS-CoV-2 on its own. Even with high rates of post-infection immunity or vaccination, behavior change
(e.g., mask use, physical distancing) may be needed to control transmission. These findings demonstra 87 le.g., mask use, physical distancing) may be needed to control transmission. These findings demonstrate the complexity
of the COVID-19 response and SARS-CoV-2 transmission and illustrate the ongoing importance of layered m 88 of the COVID-19 response and SARS-CoV-2 transmission and illustrate the ongoing importance of layered mitigation 89 approaches integrated across the public health, government, and communities. 290

91
92 **Materials and Methods**

approaches integrated across the public health, government, and communities.
Materials and Methods $\frac{1}{j}$ Experimental Design: We sought to measure the association between R_t and time-varying COVID-19 mitigation policies.
35 To accomplish this, we first modeled R_t from September 6, 2020 to November 27, 2021 (64 weeks) in To accomplish this, we first modeled R_t from September 6, 2020 to November 27, 2021 (64 weeks) in fifty-one

196 iurisdictions (all US states and DC). We then modeled the association between jurisdiction-specific R_t a go in prisdictions (all US states and DC). We then modeled the association between jurisdiction-specific R_t and policies using
Bayesian hierarchical models, explicitly adjusting for factors that directly or indirectly a 97 transmission, including personal COVID-19 mitigation behaviors, the circulation of key SARS-CoV-2 variants, weather
data, indicators of immunity, and COVID-19 vulnerability indicators. 298 data, indicators of immunity, and COVID-19 vulnerability indicators.
The analysis period was selected based on the availability of data. U.S. territories and affiliated jurisdictions were 99

 00

293

275

data, indicators
The analysis period was selected based on the availability of da
excluded from the analysis as equivalent data for policies, behavio $\frac{1}{\epsilon}$ 301 excluded from the analysis as equivalent data for policies, behaviors, SARS-CoV-2 variants, immunity, and vulnerability were not available. 02 303

 $COVID-19$ Time-varying Reproduction Number Estimation: We estimated R_t , a weekly measure of real-time transmission in each US jurisdiction, using COVID-19 case data reported to the Centers for Disease Control and
Prevention (CDC). For each reported case, an onset date was sampled from the time-specific onset-to-report dela 04
05 COVID-19 Time-varying Reproduction Number Estimation: We estimated R_t , a weekly measure of real-time
16 transmission in each US jurisdiction, using COVID-19 case data reported to the Centers for Disease Control and
17 P 306 The US is transmission in the pair and the US is the US in the US is the US is the Center of the US prevention
distribution in the national line list data set. To estimate R_t, onset dates were back projected from case re 07 distribution in the national line list data set. To estimate R_t , onset dates were back projected from case report dates using time-specific delays; infection dates were sampled using a log-normal distribution for the in distribution in the national line list data set. To estimate R_t , onset dates were back projected from case report dates
using time-specific delays; infection dates were sampled using a log-normal distribution for the in 309 mean = 1.63 and log standard deviation = 0.5 based on published data (44)]. We then generated 10 bootstrapped
samples of each jurisdictional time series using a centered 14-day moving window to account for variability in 310 samples of each jurisdictional time series using a centered 14-day moving window to account for variability in daily
reporting when estimating R_t. Finally, for each trajectory we estimated R_t using the methods describ 311 samples of each jurisdictional time series using a center we estimated R_t using the methods described in Cori et al (45).
We used a 7-day window and an uncertain serial interval (SI) (mean: 5 days, standard deviation: 1 reporting when estimating R_t. Finally, for each trajectory we estimated R_t using the methods described in Cori et al (45).
We used a 7-day window and an uncertain serial interval (SI) (mean: 5 days, standard deviation 313 14 from the SI distribution and 5 samples of the R_t posterior for each SI value (46). We thus generated 250 R_t samples for
15 each time point and jurisdiction and used the mean estimate on each Wednesday as the outcom 315 316

317

Supplement 1).

analyses.
Covariate data: We included data on mitigation policies, personal mitigation behaviors, the circulation of key variants, weather, indicators of immunity, and vulnerability indicators described below and in the Supplemental Text. We $\frac{1}{2}$ 318 Covariate data: We included data on mitigation policies, personal mitigation behaviors, the circulation of key variants,
319 weather, indicators of immunity, and vulnerability indicators described below and in the Sup 319 assessed correlation between covariates by estimating the median pairwise R^2 with bivariate regression models (see
21 Supplement 1). 321

22

 $\frac{1}{1}$ 323 COVID-19 mitigation policies: Standardized policy data were obtained from the Oxford COVID-19 Government Response
Tracker (47). The dataset includes a composite indicator (OSI) of the overall strictness of COVID-19 policie 324 of pandemic-related communication (details in Supplement 1). We used a smoothed, daily time series of jurisdiction-325 326

we also used jurisdiction-level time series for three individual policies included in the OSI indicator (cancellation of level of the values in the OSI, we also used jurisdiction-level time series for three individual policies included in the OSI
public events, restrictions on gathering 327りく 328 public events, restrictions on gathering sizes, and stay at home orders) and mask mandates from the Oxford COVID-19
Government Response Tracker (not included in OSI). We chose to examine these four policies because they we 329 public events, restrictions on gathering sizes, and stay, and started values from models of Government Response Tracker (not included in OSI). We chose to examine these four policies because they were commonly implemented 330 commonly implemented across the United States and represented key, distinct mitigation measures. We dichotomized
all policy variables into the strictest policy versus all other implementations/no policy. Data management pr 31 all policy variables into the strictest policy versus all other implementations/no policy. Data management processes for
these data are described in the Supplemental Text.
-332 333

334

these data are described in the Supplemental Text.
Personal COVID-19 mitigation behaviors: Jurisdiction-level, personal behavior data were collected from a variety of these data are described in the Supplemental Text.
Personal COVID-19 mitigation behaviors: Jurisdict
sources. Self-reported mask use in public (previous $rac{F}{c}$ 335 sources. Self-reported mask use in public (previous 5 or 7 days) and attendance at gatherings (in the past 24 hours) were collected from the COVID-19 Trends and Impact Survey of Facebook users (48, 49) (See Supplemental Fi 336 collected from the COVID-19 Trends and Impact Survey of Facebook users (48, 49) (See Supplemental Figure 2); mobility
data were collected from Google's COVID-19 Community Mobility Reports (50); and national travel estimate 337 collected from the COVID-19 Trends and impact Survey of Facebook users (40, 49) (See Supplemental Figure 2), mobility
data were collected from Google's COVID-19 Community Mobility Reports (50); and national travel estimate 338 data were conceted from Google's COVID-19 Community Mobility Reports (50), and national travel estimates were
collected from the Transportation Security Administration (51). From the Community Mobility Report data, we incl 339 conceted from the Transportation Security Administration (51). From the community Wobility Report data, we included
the proportional reduction in weekly median mobility to retail and recreation locations relative to baseli 340 January 3- February 6, 2020. We also included the weekly median reduction in national airline travel relative to
maximum weekly travel in 2019. We set the reference to the maximum weekly travel in 2019 to ease interpretati 341 maximum weekly travel in 2019. We set the reference to the maximum weekly travel in 2019 to ease interpretation of
the coefficients in the final model. 342 343

344

Circulation of key SARS-CoV-2 variants: We estimated the weekly proportion of Alpha (B.1.1.7) and Delta (B.1.617.2) Circulation of key SARS-CoV-2 var
SARS-CoV-2 variants in circulation $\frac{6}{1}$ 345 Chromatical time of the circulation of the weekly proportion of Alpha (B.1.1.7) and Delta (B.1.1.1.7)
SARS-CoV-2 variants in circulation by fitting sequence data to a multinomial logistic regression model, which included
n 346 normalized survey weights to account for reporting patterns within and between jurisdictions (52).
Weather data: We pulled temperature (°C) data from weather stations included in the National Oceanic and 347 348

normalized survey weights to account for reporting patterns within and between jurisdictions (52).
Weather data: We pulled temperature (°C) data from weather stations included in the N
Atmospheric Administration's Integrat $\frac{1}{2}$ 349 Atmospheric Administration's Integrated Surface Database (53), using the package "worldmet" (54). From station level
data, we calculated the weekly median temperature in each jurisdiction. Given the role of humidity in res 350 Atmospheric Administration's integrated Surface Database (55), using the package "worldmet" (54). From station level
data, we calculated the weekly median temperature in each jurisdiction. Given the role of humidity in res 351 data, we calculated the week and temperature in each jurisdiction. The role of humidity, in respiratory virus
transmission (55, 56), we also assessed associations with relative humidity and absolute humidity to guide our m 352 transmission (55, 56), we also assessed associations with relative humanty and absolute humanty to guide our modeling
(Supplemental Figure 3).
Indicators of immunity: We included infection-acquired and vaccine-derived immu 353

354

(Supplemental Figure 3).
<u>Indicators of immunity</u>: 1
Models. As a proxy mea $\frac{1}{r}$ 55 INDICATE: INTERTMINING INTERTMINING INTERTMINING INTERTMINING INTERTMINING INTERTMINING INCORDING INCORDING IN
Indicators of intervals of infection-acquired immunity, we modeled jurisdiction-level seroprevalence, adjusting 356 models. As a proxy measure of models. As a minimum, the included jurisdiction-correspondence, any acting
and colleagues using data from national SARS-CoV2 serosurveys (57). For vaccination, we used the weekly jurisdictiona 357 and colleagues using data from national SARS-CoV2 serosurveys (57). For vaccination, we used the weekly jurisdictional
percentage of individuals with a completed primary series of COVID-19 vaccine (58). 358 359

360

COVID-19 vulnerability indicators: We included variables that represent static underlying components that influence transmission, which were developed as part of the CCVI (59) and range from 0 to 1 across all jurisdictions: 1) Racial and
Ethnic Diversity 2) Percentage of Population Working or Living in Environments with High COVID-19 In $\frac{c}{t}$ 61 COVITE: THE INTERT INTERT IN THE TERM OF THE INTERTMENT THAT THE INTERTMENT IN THE INTERTMENT IN REGILED IN TH
COVID-19 Infection Sisk, 3)
Socioeconomic Status, 4) Housing type, Transportation, Household Composition and Di 62 transmission, which were developed as part of the CCVI (55) and range from 0 to 1 across an jarisdictions: 1) Racial and
Ethnic Diversity 2) Percentage of Population Working or Living in Environments with High COVID-19 Inf 363 Socioeconomic Status, 4) Housing type, Transportation, Household Composition and Disability, and 5) Population
Density (see Supplemental Figure 4 for Pearson correlation coefficients for CCVI indicators, and Supplemental F 364 Density (see Supplemental Figure 4 for Pearson correlation coefficients for CCVI indicators, and Supplemental Figure 5
for spatial distribution and correlation with time-varying covariates). 65 Density (SCCO) production and correlation with time-varying covariates).
Density for Spatial distribution and correlation with time-varying covariates).
Statistical Analysis: We assessed the association between R_t and se 366

67

for spatial distribution and correlation time-varying covariates).
Statistical Analysis: We assessed the association between R_t and se
level regression models, using a log-link function and jurisdiction- $\frac{1}{6}$ Statistical Analysis: We assessed the association between R_t and selected determinants with Bayesian Gaussian multi-
S9 Level regression models, using a log-link function and jurisdiction- and time-specific intercepts (69 account for spatiotemporal autocorrelation). We assessed two models. The first focused on general government 370 account for spatiotemporal autocorrelation). We assessed two models. The first focused on general government
The first focused on general government government government government government

371 public events, restrictions on gathering sizes, stay at home orders, and mask mandates. Both models were adjusted for
the aforementioned covariates (Supplemental Text for model statements). For each model, we ran four Mark 372 public exemptions, restrictions on gathering sizes, stay at the orders, and material forecast the aforementioned covariates (Supplemental Text for model statements). For each model, we ran four Markov chains
at 2,500 itera 373 at 2,500 iterations each, with a burn in period of 1,250 iterations. We specified priors for an expected negative
association for all components likely to decrease transmission (OSI, all individual mitigation policies, mob 374 association for all components likely to decrease transmission (OSI, all individual mitigation policies, mobility, masking, reduced airline travel, cumulative COVID-19 cases, vaccination, and temperature) or expected posit 375 reduced airline travel, cumulative COVID-19 cases, vaccination, and temperature) or expected positive association for 376 those which may increase transmission (variants and each CCVI indicator). Priors were specified on the log-scale. For
each coefficient with an expected negative association, we used a normal distribution with a mean of -0. 377 that may increase transmission (variant and each contract may be transmissed transmission of 0.7 and standard
deviation of 0.1, approximating a 50% decrease with a 95% CI of 40-60%. We used a normal prior with a mean of 0. 378 deviation of 0.1, approximating a 50% decrease with a 95% CI of 40-60%. We used a normal prior with a mean of 0.4 and
a standard deviation of 0.1 for covariates with expected positive associations, approximating a 50% inc 379 a standard deviation of 0.1 for covariates with expected positive associations, approximating a 50% increase with a 95%
CI of 20-80%. The intercept prior had a normal distribution with a mean of 1.1 and standard deviation 380 CI of 20-80%. The intercept prior had a normal distribution with a mean of 1.1 and standard deviation of 0.1, reflecting
an expected R_t without any mitigation behaviors or policies from 2.5 to 3.7 (95% CI). Model conver 81 an expected R_t without any mitigation behaviors or policies from 2.5 to 3.7 (95% CI). Model convergence was assessed
using the Gelman-Rubin convergence diagnostic (\hat{R}) and model fit was evaluated from the predictiv 383 384

Jurisdiction-specific results for the OSI model are presented in Supplemental Figure 7.
We conducted several sensitivity analyses. First, we compared these models to the same two models with naïve priors
via leave-one-out In the model fit was evaluated from the prediction.

Inted in Supplemental Figure 7.

Sompared these models to the same two models with naïve priors. Jurisdiction-specific results:
Jurisdiction-specific results for the Supplemental Figures for the Supplemental Figures 6) and comparer
Jurisdiction-Supplemental Figures 6) and comparer ー
ト
オ 386 We can be conducted sensitivity analysis of the semi-particle servers of the same of the series of the series for temporal correlation (Supplemental Figures 8). Second, we re-ran the primary models using publicly availabl 387 For temporal correlation (Supplemental Figures 8). Second, we re-ran the primary models using publicly available R_t estimates from the Centre for Mathematical Modeling of Infectious Diseases COVID modelling group (61) a 388 estimates from the Centre for Mathematical Modeling of Infectious Diseases COVID modelling group (61) and compared
the model results to those presented here (Supplemental Figures 9). Third, we re-ran the individual policy 389 estimates from the Centre for Mathematical Modeling of Infectious Diseases COVID modeling group (61) and compared
the model results to those presented here (Supplemental Figures 9). Third, we re-ran the individual policy m 390 the model results to those presented here (supplemental Figures 10).
Without the behavior covariates (Supplemental Figures 10).
Analyses were conducted using R (version 4.2.1), with the *rstanarm* package used for primary 91

white the behavior covariates (supplemental Figures 20).
Analyses were conducted using R (version 4.2.1), with th
available in a public repository (https://github.com/cdcepi/($\frac{1}{c}$ 393 Analyses were conducted using R (version 4.2.1), with the rstanding package used for primary analyses. R code is
available in a public repository (https://github.com/cdcepi/COVID-19-Mitigation_Rt).
This activity was review 394

This activity was reviewed by CDC and was conducted consistent with applicable fede 96 This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy¹⁹.
27

 \overline{a} This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy*°.
CDC disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily rep
o $\frac{1}{2}$ 38 CDC disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the
39 official position of the U.S. Centers for Disease Control and Prevention.
30 **References** 99

01 References

385

392

395

397

400

- official position of the U.S. Centers for Disease Control and Prevention.
The U.S. Centers for Disease Control and Prevention.
The U.S. Centers for Disease Control and Prevention. **I** 403 1. M. Biggerstaff, S. Cauchemez, C. Reed, M. Cambridge, C. Reedsign, S. Cauchemeter, AMC Infect. Dis. 14, 1–20
(2014).
2. Y. Liu, A. A. Gayle, A. Wilder-Smith, J. Rocklöv, The reproductive number of COVID-19 is higher comp 404 405
- seasonal, pandemic, and zoonotic influenza: A systematic review of the literature. BMC Infect. Dis. 14, 1–20
(2014).
2. Y. Liu, A. A. Gayle, A. Wilder-Smith, J. Rocklöv, The reproductive number of COVID-19 is higher compar (2014).
2. Y. Liu, A. A. Gayle, A. Wilder-Smith, J. Rocklöv, The reproductive number of COVID-19 is higher compared
to SARS coronavirus. *J. Travel Med. 2*7, 1–4 (2020).
3. J. M. Brauner, S. Mindermann, M. Sharma 406 407
- to SARS coronavirus. *J. Travel Med.* 27, 1–4 (2020).
3. J. M. Brauner, S. Mindermann, M. Sharma, D. Johnston, J. Salvatier, T. Gavenčiak, A. B. Stephenson, G
Leech, G. Altman, V. Mikulik, A. J. Norman, J. T. Monrad, to SARS coronavirus. J. *Havel Med. 21*, 1–4 (2020).
3. J. M. Brauner, S. Mindermann, M. Sharma, I
Leech, G. Altman, V. Mikulik, A. J. Norman, J. T. I
Chindelevitch, Y. Gal, J. Kulveit, Inferring the effe 408 3. Jeech, G. Altman, V. Mikulik, A. J. Norman, J. T. Monrad, T. Besiroglu, H. Ge, M. A. Hartwick, Y. W. Teh, L.
Chindelevitch, Y. Gal, J. Kulveit, Inferring the effectiveness of government interventions against COVID-19.
S 409 Lettin, G. Altman, G. Altman, V. Micropolitical, C. Altman, J. Microsoft, M. G. Altman, M. A. H. Georgian, C.
Science. **371** (2021).
4. S. Flaxman, S. Mishra, A. Gandy, H. J. T. Unwin, T. A. Mellan, H. Coupland, C. Whittak 410
- *Science*. **371** (2021).
4. S. Flaxman, S. Mishra, A. Gandy, H. J. T. Unwin, T. A. Mellan, H. Coupland, C. Whittaker, H. Zhu, T. Berah,
J. W. Eaton, M. Monod, P. N. Perez-Guzman, N. Schmit, L. Cilloni, K. E. C. Ainsl 11 Science. **371** (2021).

12 4. S. Flaxman, S.

13 J. W. Eaton, M. Mon

14 Boyd, L. Cattarino, L. 412 J. W. Eaton, M. Monod, P. N. Perez-Guzman, N. Schmit, L. Cilloni, K. E. C. Ainslie, M. Baguelin, A. Boonyasiri, O.
Boyd, L. Cattarino, L. V. Cooper, Z. Cucunubá, G. Cuomo-Dannenburg, A. Dighe, B. Djaafara, I. Dorigatti, S. 413 J. W. Extern, M. Monod, D. W. Perez-Guzman, M. Schmit, A. Bourn, A. Bourn, M. Boghem, M. Bourn, M. Bourn, B. D
Boyd, L. Cattarino, L. V. Cooper, Z. Cucunubá, G. Cuomo-Dannenburg, A. Dighe, B. Djaafara, I. Dorigatti, S. L.
 414 11, S. Cattarino, R. G. FitzJohn, K. A. M. Gaythorpe, L. Geidelberg, N. C. Grassly, W. D. Green, T. Hallett, A. Hamlet,
W. Hinsley, B. Jeffrey, E. Knock, D. J. Laydon, G. Nedjati-Gilani, P. Nouvellet, K. V. Parag, I. Siver 415 W. Hinsley, B. Jeffrey, E. Knock, D. J. Laydon, G. Nedjati-Gilani, P. Nouvellet, K. V. Parag, I. Siveroni, H. A.
Thompson, R. Verity, E. Volz, C. E. Walters, H. Wang, Y. Wang, O. J. Watson, P. Winskill, X. Xi, P. G. T. Wal 416 Thompson, R. Verity, E. Volz, C. E. Walters, H. Wang, Y. Wang, O. J. Watson, P. Winskill, X. Xi, P. G. T. Walker, A.

Thompson, R. Verity, E. Volz, C. E. Walters, H. Wang, Y. Wang, O. J. Watson, P. Winskill, X. Xi, P. G. 417

Thompson, R. Verity, E. Volz, C. E. Walters, H. Wang, Y. Wang, O. J. Watson, P. Winskill, X. Xi, P. G. T. Walker, A. -1§ See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

418

419

420

421

22

423

24

425

426

27

428

29

430

431

32

433

434

435

436

438

39

440

441

42

443

444

45

446

47

448

449

450

451

452

453

454

455

457

458

59

460

461

non-pharmaceutical interventions on COVID-19 in Europe. *Nat. 2020 5847820*. **584**, 257–261 (2020).
5. N. Haug, L. Geyrhofer, A. Londei, E. Dervic, A. Desvars-Larrive, V. Loreto, B. Pinior, S. Thurner, P. Klimek,
Ran non-pharmaceutical interventions on COVID-19 in Europe. Nat. 2020 5847820. **584**, 257–261 (2020).
5. N. Haug, L. Geyrhofer, A. Londei, E. Dervic, A. Desvars-Larrive, V. Loreto, B. Pinior, S. Thurner,
Ranking the effectiven 5. Nanking the effectiveness of worldwide COVID-19 government interventions. Nat. Hum. Behav. 2020 412. 4,
1303–1312 (2020).
6. A. Asfaw, Racial and Ethnic Disparities in Teleworking Due to the COVID-19 Pandemic in the Uni

1303–1312 (2020).
6. A. Asfaw, Racial and Ethnic Disparities in Teleworking Due to the COVID-19 Pandemic in the United
States: A Mediation Analysis. *Int. J. Environ. Res. Public Health 2022 Vol 19 Page 4680*. **19**, 46 States: A Mediation Analysis. Int. J. Environ. Res. Public Health 2022 Vol 19 Page 4680. 19, 4680 (2022).

7. T. N. Rogers, C. R. Rogers, E. VanSant-Webb, L. Y. Gu, B. Yan, F. Qeadan, Racial Disparities in COVID-19
Mortality Among Essential Workers in the United States. World Med. Health Policy. 12, 311–327 (2020).
8. J. Gaiten Mortality Among Essential Workers in the United States. World Med. Health Policy. 12, 311-327 (2020).

Mortality Among Essential Workers in the United States. World Med. Health Policy. 12, 311–327 (2020).
8. J. Gaitens, M. Condon, E. Fernandes, M. McDiarmid, COVID-19 and Essential Workers: A Narrative
Review of Health Outco Mortality Among Essential Workers in the United States. World Med. Health Policy. 12, 311–327 (2020).
8. J. Gaitens, M. Condon, E. Fernandes, M. McDiarmid, COVID-19 and Essential Workers: A Na
Review of Health Outcomes and Review of Health Outcomes and Moral Injury. *Int. J. Environ. Res. Public Health 2021 Vol 18 Page 1446*. **18,**
1446 (2021).
9. C. DiMaggio, M. Klein, C. Berry, S. Frangos, Black/African American Communities are at high

Review of Health Outcomes and Moral Injury. *Int. J. Environ.* Res. Public Health 2021 Vol 18 Page 1446. 18,
1446 (2021).
C. DiMaggio, M. Klein, C. Berry, S. Frangos, Black/African American Communities are at highest risk 1446 (2021).

9. COVID-19: spatial modeling of New York City ZIP Code–level testing results. Ann. Epidemiol. 51, 7–13 (2020).
10. D. S. Grigsby-Toussaint, J. C. Shin, A. Jones, Disparities in the distribution of COVID-19 testing sites i 10. D. S. Grigsby-Toussaint, J. C. Shin, A. Jones, Disparities in the distribution of COVID-19 testing sites in
black and Latino areas in new York City. *Prev. Med.* **147**, 106463 (2021).
11. A. Mody, K. Pfeifauf,

black and Latino areas in new York City. *Prev. Med.* **147**, 106463 (2021).
11. A. Mody, K. Pfeifauf, C. Bradley, B. Fox, M. G. Hlatshwayo, W. Ross, V. Sanders-Thompson, K. Joynt
Maddox, M. Reidhead, M. Schootman, W. black and Latino areas in new York City. *Prev. Med.* 147, 100463 (2021).
11. A. Mody, K. Pfeifauf, C. Bradley, B. Fox, M. G. Hlatshwayo, W.
Maddox, M. Reidhead, M. Schootman, W. G. Powderly, E. H. Geng,
Disease 2019 (COVI 11. Maddox, M. Reidhead, M. Schootman, W. G. Powderly, E. H. Geng, Understanding Drivers of Coronavirus
Disease 2019 (COVID-19) Racial Disparities: A Population-Level Analysis of COVID-19 Testing Among Black and
White Popu Disease 2019 (COVID-19) Racial Disparities: A Population-Level Analysis of COVID-19 Testing Among Black and
White Populations. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **73**, e2921–e2931 (2021).
12. T. P. S

White Populations. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 73, e2921–e2931 (2021).

12. T. P. Smith, S. Flaxman, A. S. Gallinat, S. P. Kinosian, M. Stemkovski, H. Juliette, O. J. Watson, C.

139 Whittaker, L. C Whittaker, L. Cattarino, I. Dorigatti, M. Tristem, W. D. Pearse, Temperature and population density influence
SARS-CoV-2 transmission in the absence of nonpharmaceutical interventions. *Proc. Natl. Acad. Sci. U. S. A.* 118 SARS-CoV-2 transmission in the absence of nonpharmaceutical interventions. Proc. Natl. Acad. Sci. U. S. A. 118,
e2019284118 (2021).
13. D. Schoeman, B. C. Fielding, Coronavirus envelope protein: current knowledge. *Virol.*

13. D. Schoeman, B. C. Fielding, Coronavirus envelope protein: current knowledge. *Virol. J. 2019 161*. **16,** 1–
22 (2019).
14. L. Hallas, M. Pyarali, T. Hale, A. Professor, A. Brown, A. Sudarmawan, A. Detmar, A. H 13. D. Schoeman, B
22 (2019).
14. L. Hallas, M. Py

13. – D. Schoeman, B. C. Fielding, Coronavirus envelope protein: current knowledge. *Virol. J. 2015* 101. **10**, 1
22 (2019).
14. – L. Hallas, M. Pyarali, T. Hale, A. Professor, A. Brown, A. Sudarmawan, A. Detmar, A. Hatibi 14 L. H.
B. Bacyte,
D. Roberts B. Bacyte, C. Lumley, D.-Y. Li, E. Kanzig, G. Mortell, G. Xu, H. Klim, H. Jow, H. McGuire, I. Clancy, J. Ng, J. Chan,
D. Roberts, J. Uhm, K. Green, K. McCreery, K. Kon, Variation in US states' responses to COVID-19 (2021), B. Roberts, J. Uhm, K. Green, K. McCreery, K. Kon, Variation in US states' responses to COVID-19 (2021),
(available at https://www.bsg.ox.ac.uk/research/publications/variation-us-states-responses-covid-19).
15. Centers f

and the state of the
(available at https://www.bsg.ox.ac.uk/research/publications/variation-us-states-responses-covid-19).
15. Cent (available at https://www.bsg.on.com/publications/variation-us-trates-response control at 15.
15. Centers for Disease Control and Prevention (CDC), CDC COVID Data Tracker: Home, (avail
https://covid.cdc.gov/covid-data-trac

15. Centers for Disease Control and Prevention (CDC), CDC COVID Data Tracker: Home, (available at
https://covid.cdc.gov/covid-data-tracker/#datatracker-home).
16. C. Courtemanche, J. Garuccio, A. Le, J. Pinkston, A. Yelowi united states reduced the covid-19 growth rate. Health Aff. (Millwood). 39, 1237-1246 (2020).

united states reduced the covid-19 growth rate. *Health Aff. (Millwood)*. **39**, 1237–1246 (2020).
17. N. N. Lurie, J. Silva, R. R. Yorlets, J. Tao, P. A. Chan, Coronavirus disease 2019 epidemic doubling time in
the United united states reduced the covid-19 growth rate. Health Aff. (Millwood). 39, 1237–1246 (2020).
17. M. N. Lurie, J. Silva, R. R. Yorlets, J. Tao, P. A. Chan, Coronavirus disease 2019 epidemic
the United States before and dur

17. M. H. M. Lurie, J. M. M. H. M. H. M. R. R. M. M. Lurie, J. M. M. D. 222, 1601–1606 (2020).
18. M. J. Siedner, G. Harling, Z. Reynolds, R. F. Gilbert, S. Haneuse, A. S. Venkataramani, A. C. Tsai, Social
distancing to sl the United States before and during stay-at-home restrictions. J. Inject. Dis. 222, 1601–1606 (2020).
18. M. J. Siedner, G. Harling, Z. Reynolds, R. F. Gilbert, S. Haneuse, A. S. Venkataramani, A. C.
distancing to slow the distancing to slow the US COVID-19 epidemic: Longitudinal pretest–posttest comparison group study. *PLoS
Med.* 17, 1–12 (2020).
19. G. A. Wellenius, S. Vispute, V. Espinosa, A. Fabrikant, T. C. Tsai, J. Hennessy, A. Dai,

distancing to slow the US COVID-19 epidemic: Longitudinal pretest–posttest comparison group study. PLoS

456 Med. 17, 1–12 (2020).

456 Gadepalli, A. Boulanger, A. Pearce, C. Kamath, A. Schlosberg, C. Bendebury, C. Mandaya 19. Gadepalli, A. Boulanger, A. Pearce, C. Kamath, A. Schlosberg, C. Bendebury, C. Mandayam, C. Stanton, S.
Bavadekar, C. Pluntke, D. Desfontaines, B. H. Jacobson, Z. Armstrong, B. Gipson, R. Wilson, A. Widdowson, K.
Chou, Bavadekar, C. Pluntke, D. Desfontaines, B. H. Jacobson, Z. Armstrong, B. Gipson, R. Wilson, A. Widdowson, K.
Chou, A. Oplinger, T. Shekel, A. K. Jha, E. Gabrilovich, Impacts of social distancing policies on mobility and
CO Chou, A. Oplinger, T. Shekel, A. K. Jha, E. Gabrilovich, Impacts of social distancing policies on mobility and
COVID-19 case growth in the US. Nat. Commun. 12, 6–12 (2021).
20. N. Liu, X. Xu, G. Li, X. Xu, Y. Sun, F. Wang,

COVID-19 case growth in the US. *Nat. Commun.* **12**, 6–12 (2021).
20. X. Liu, X. Xu, G. Li, X. Xu, Y. Sun, F. Wang, X. Shi, X. Li, G. Xie, L. Zhang, Differential impact of non-
pharmaceutical public health intervention COVID-19 case growth in the US. Nat. Commun. 12, 6–12 (2021).
20. X. Liu, X. Xu, G. Li, X. Xu, Y. Sun, F. Wang, X. Shi, X. Li,
pharmaceutical public health interventions on COVID-19 epiden
21, 1–7 (2021). 462 463 pharmaceutical public health interventions on COVID-19 epidemics in the Oniced States. BMC Public Health.
21, 1–7 (2021). 64 **21**, $1-7$ (2021).

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

82

483

485

486

487

488

89

490

491

492

493

494

495

497

498

499

500

 01

502

03

504

505

506

507

508

509

21. N. Dreher, Z. Spiera, F. M. McAuley, L. Kuohn, J. R. Durbin, N. F. Marayati, M. Ali, A. Y. Li, T. C. Hannah, A.
Gometz, J. T. Kostman, T. F. Choudhri, Policy Interventions, Social Distancing, and SARS-CoV-2 Transmissio

Gometz, J. Cometz, J. T. Antionalis, J. M. F. Choudhri, J. Med. Sci. 361, 575–584 (2021).
22. B. Yang, A. T. Huang, B. Garcia-Carreras, W. E. Hart, A. Staid, M. D. T. Hitchings, E. C. Lee, C. J. Howe, K
H. Grantz, A. Wesol the United States: A Retrospective State-lever Analysis. Am. J. Med. Sci. 361, 375–584 (2021).
22. B. Yang, A. T. Huang, B. Garcia-Carreras, W. E. Hart, A. Staid, M. D. T. Hitchings, E. C. L
H. Grantz, A. Wesolowksi, J. C. H. Grantz, A. Wesolowksi, J. C. Lemaitre, S. Rattigan, C. Moreno, B. A. Borgert, C. Dale, N. Quigley, A.
Cummings, A. McLorg, K. LoMonaco, S. Schlossberg, D. Barron-Kraus, H. Shrock, J. Lessler, C. D. Laird, H.-L. Yau,
D. Cummings, A. McLorg, K. LoMonaco, S. Schlossberg, D. Barron-Kraus, H. Shrock, J. Lessler, C. D. Laird, H.-L. Yau, D. A. T. Cummings, Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in D. A. T. Cummings, Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in
the counties of the United States. Nat. Commun. 12, 3560 (2021).
23. M. E. Van Dyke, T. M. Rogers, E. Pevzner, C.

D. A. T. Cummings, Effect of Specific Interpretation provides the specific of the counties of the United States. Nat. Commun. 12, 3560 (2021).
23. M. E. Van Dyke, T. M. Rogers, E. Pevzner, C. L. Satterwhite, H. B. Shah, W. the counties of the United States. Nat. Commun. 12, 3360 (2021).
23. M. E. Van Dyke, T. M. Rogers, E. Pevzner, C. L. Satterwhite
Hunt, J. Rule, Trends in County-Level COVID-19 Incidence in Cou
Kansas, June 1–August 23, 202 Hunt, J. Rule, Trends in County-Level COVID-19 Incidence in Counties With and Without a Mask Mandate —
Kansas, June 1–August 23, 2020. *MMWR Morb. Mortal. Wkly. Rep.* 69, 1777–1781 (2022).
24. H. Joo, G. F. Miller, G.

Kansas, June 1–August 23, 2020. *MMWR Morb. Mortal. Wkly. Rep.* 69, 1777–1781 (2022).
24. H. Joo, G. F. Miller, G. Sunshine, M. Gakh, J. Pike, F. P. Havers, L. Kim, R. Weber, S. Dugmeoglu, C.
Watson, F. Coronado, Decli Kansas, Jane 1–August 23, 2020. *MMWR Morb. Mortal. WKI). Rep.* 03, 1777–1781 (2022).
24. H. Joo, G. F. Miller, G. Sunshine, M. Gakh, J. Pike, F. P. Havers, L. Kim, R. Web.
Watson, F. Coronado, Decline in COVID-19 Hospital 24. H. J. J. J. J. J. H. J. J. H. J. H. J. H. J. H. J. H. J. H. H. J. H. H. J. H. H. H. J. H. H. J. H. H. H. H
Watson, F. Coronado, Decline in COVID-19 Hospitalization Growth Rates Associated with Statewide Mask
Mandates —

Watson, F. Coronalisty, F. Coronalisty, F. Coronalisty, Mandates - 10 States, March-October 2020. *MMWR Morb. Mortal. Wkly. Rep.* **70**, 212–216 (2021).
25. S. Singh, M. Shaikh, K. Hauck, M. Miraldo, Impacts of introducing Mandates The States, March–October 2020. MMWR Morb. Mortal. Wkly. Rep. 70, 212–216 (2021).
25. S. Singh, M. Shaikh, K. Hauck, M. Miraldo, Impacts of introducing and lifting nonpharn
interventions on COVID-19 daily growth r interventions on COVID-19 daily growth rate and compliance in the United States. Proc. Natl. Acad. Sci. U. S. A.
118, 1–9 (2021).
26. H. Y. Chang, W. Tang, E. Hatef, C. Kitchen, J. P. Weiner, H. Kharrazi, Differential

interventions on COVID-19 daily growth rate and compliance in the United States. Proc. Natl. Acad. Sci. U. S. A.
118, 1–9 (2021).
Policies and socioeconomic status on COVID-19 prevalence and social distancing in the Unit 81 **118**, 1–9 (2021).

82 26. H. Y. Char

83 policies and soci

84 *Public Health*. 21 26. H. Y. H. Y. Chang, W. H. W. Y. Y. H. Hatef, M. H. Hatef, M. Hatefall, P. H. Hatefall, M. Hamgearth.
Public Health. 21, 1–10 (2021).
27. M. A. Crane, K. M. Shermock, S. B. Omer, J. A. Romley, Change in Reported Adherenc

policies and socioeconomic status on COVID-19 prevalence and social distancing in the Onited States. BMC
Public Health. **21**, 1–10 (2021).
Nonpharmaceutical Interventions During the COVID-19 Pandemic, April-November 2020. 84 Public Health. **21**, 1–10 (2021).

85 27. M. A. Crane, K. M. S

86 Nonpharmaceutical Interventio

87 (2021). Nonpharmaceutical Interventions During the COVID-19 Pandemic, April-November 2020. JAMA. **325**, 883–885
(2021).
28. J. N. Sanchez, G. A. Reyes, B. Martínez-López, C. K. Johnson, Impact of social distancing on early SAR

(2021).
28. J. N. Sanchez, G. A. Reyes, B. Martínez-López, C. K. Johnson, Impact of social distancing on early SARS-
CoV-2 transmission in the United States. *Zoonoses Public Health,* 1–11 (2022).
29. S. Gupta, T. Nguyen, CoV-2 transmission in the United States. Zoonoses Public Health, 1-11 (2022).

28. J. N. Sanchez, G. A. Reyes, B. Martínez-López, C. K. Johnson, Impact of social distancing on early SARS-Cov-2 transmission in the United States. Zoonoses Public Health, 1–11 (2022).
29. S. Gupta, T. Nguyen, S. Raman, B. Lee, F. Lozano-Rojas, A. Bento, K. Sim
Private Responses to the COVID-19 Epidemic. *https://doi.org/10.108*

Private Responses to the COVID-19 Epidemic. *https://doi.org/10.1086/716197.* **7**, 361–404 (2021).
30. M. É. Czeisler, M. A. Tynan, M. E. Howard, S. Honeycutt, E. B. Fulmer, D. P. Kidder, R. Robbins, L. K.
Barger, E. R Private Responses to the COVID-19 Epidemic. *https://doi.org/10.1080/710197.* 7, 301–404 (2021).
30. M. É. Czeisler, M. A. Tynan, M. E. Howard, S. Honeycutt, E. B. Fulmer, D. P. Kidder, R. R.
Barger, E. R. Facer-Childs, G. Barger, E. R. Facer-Childs, G. Baldwin, S. M. W. Rajaratnam, C. A. Czeisler, Public Attitudes, Behaviors, and
Beliefs Related to COVID-19, Stay-at-Home Orders, Nonessential Business Closures, and Public Health
Guidance — U Beliefs Related to COVID-19, Stay-at-Home Orders, Nonessential Business Closures, and Public Health
Guidance — United States, New York City, and Los Angeles, May 5–12, 2020. *MMWR Morb. Mortal. Wkly. Rep.*
69, 751–758 (202 Guidance — United States, New York City, and Los Angeles, May 5–12, 2020. *MMWR Morb. Mortal. Wkly. Rep.*
69, 751–758 (2020).
31. C. R. Berry, A. Fowler, T. Glazer, S. Handel-Meyer, A. MacMillen, Evaluating the effects of

31. C. R. Berry, A. Fowler, T. Glazer, S. Handel-Meyer, A. MacMillen, Evaluating the effects of shelter-in-
place policies during the COVID-19 pandemic. *Proc. Natl. Acad. Sci. U. S. A.* 118, 1–6 (2021).
32. C. Pingali, M. 96 **69**, 751–758 (2020).

97 31. C. R. Berry, A

98 place policies during

99 32. C. Pingali, M.

31. C. R. Berry, A. Fowler, T. Glazer, S. Handel-Meyer, A. MacMillen, Evaluating the effects of shelter-inplace policies during the COVID-19 pandemic. *Proc. Nuti. Acud. Sci. O. S. A.* 116, 1–6 (2021).
32. C. Pingali, M. Meghani, H. Razzaghi, ; Mark, J. Lamias, E. Weintraub, ; Tat', Y. A. Ken
N. Lewis, ; Bruce Fireman, ; Ousse 12. Lewis, ; Bruce Fireman, ; Ousseny Zerbo, J. Bartlett, K. Goddard, J. Donahue, K. Hanson, A. Naleway, E. O.
Kharbanda, ; W Katherine Yih, ; Jennifer, C. Nelson, ; Bruno, J. Lewin, J. T. B. Williams, J. M. Glanz, J. A.
S Kharbanda, ; W Katherine Yih, ; Jennifer, C. Nelson, ; Bruno, J. Lewin, J. T. B. Williams, J. M. Glanz, J. A.
Singleton, S. A. Patel, COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by
Race/Ethnicity a Singleton, S. A. Patel, COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by
Race/Ethnicity and Other Selected Characteristics-Eight. 70 (2021) (available at
https://www.cdc.gov/mmwr/mmwr_continuingEduca Race/Ethnicity and Other Selected Characteristics-Eight. **70** (2021) (available at
https://www.cdc.gov/mmwr/mmwr_continuingEducation.html).
33. G. Milne, T. Hames, C. Scotton, N. Gent, A. Johnsen, R. M. Anderson, T. Ward,

Race/Ethnicity and Other Selected Characteristics-Eight. 70 (2021) (available at
https://www.cdc.gov/mmwr/mmwr_continuingEducation.html).
33. G. Milne, T. Hames, C. Scotton, N. Gent, A. Johnsen, R. M. Anderson, T. Ward, Do https://www.cdc.gov/mmwr/mmwr_continuingEducation.html).
33. G. Milne, T. Hames, C. Scotton, N. Gent, A. Johnsen, R. M. Anderson, T. Ward, Does infection with or
vaccination against SARS-CoV-2 lead to lasting immunity? *La*

P. R. Krause, T. R. Fleming, I. M. Longini, R. Peto, S. Briand, D. L. Heymann, V. Beral, M. D. Snape, H. Rees, vacemation against SARS-Cov-2 lead to lasting immunity? *Lancet Respir. Med. 3,* 1450–1466 (2021).
34. P. R. Krause, T. R. Fleming, I. M. Longini, R. Peto, S. Briand, D. L. Heymann, V. Beral, M. D. Snap
A.-M. Ropero, R. D. A.-M. Ropero, R. D. Balicer, J. P. Cramer, C. Muñoz-Fontela, M. Gruber, R. Gaspar, J. A. Singh, K. Subbarao, M.
D. Van Kerkhove, S. Swaminathan, M. J. Ryan, A.-M. Henao-Restrepo, SARS-CoV-2 Variants and Vaccines. *N.*
Engl A. M. Ropers, R. D. Balicer, R. P. Balicer, J. Romanne, A. Balicer, A. Balicer, R. Balph, R. Ropers, A. D. Van
Engl. J. Med. **385**, 179–186 (2021).
35. L. E. Egede, R. J. Walker, Structural Racism, Social Risk Factors, and

D. Van Kerkhove, S. Swammathan, M. J. Ryan, A.-M. Henao-Restrepo, SARS-Cov-2 Variants and Vaccines. N.
Engl. J. Med. **385**, 179–186 (2021).
35. L. E. Egede, R. J. Walker, Structural Racism, Social Risk Factors, and Covid-1 10 Engl. J. Med. **385**, 179–186 (2021).
11 35. L. E. Egede, R. J. Walker,
12 Convergence for Black Americans. I 11 35. Convergence for Black Americans. N. Engl. J. Med. 383, e77 (2020). 512 Convergence for Black Americans. N. Engl. J. Med. 383, e77 (2020).

36. G. A. Noppert, L. C. Zalla, Who Counts and Who Gets Counted? Health Equity in Infectious Disease
Surveillance. Am. J. Public Health. 111, 1004–1006 (2021).
37. K. Bibbins-Domingo, This Time Must Be Different: Dispariti 513 36. 514 515 37. Kritpsdoiorg107326M20-2247. **173**, 233–234 (2020).
38. S. Dasgupta, V. B. Bowen, A. Leidner, K. Fletcher, T. Musial, C. Rose, A. Cha, G. Kang, E. Dirlikov, E.
Pevzner, D. Rose, M. D. Ritchey, J. Villanueva, C. Philip, Httpsdoiorg107326M20-2247. 173, 233-234 (2020). Httpsdoiorg107326M20-2247. 173, 233–234 (2020).

52. S. Dasgupta, V. B. Bowen, A. Leidner, K. Fletcher, T. Musial, C. Rose, A. Cha, G. Kang, E. Dirlikov, E.

53. S. Dasgupta, V. B. Bowen, A. Leidner, K. Fletcher, T. Musial 517 Pevzner, D. Rose, M. D. Ritchey, J. Villanueva, C. Philip, L. Liburd, A. M. Oster, Association Between Social
Vulnerability and a County's Risk for Becoming a COVID-19 Hotspot — United States, June 1–July 25, 2020.
Morb. M 518 Vulnerability and a County's Risk for Becoming a COVID-19 Hotspot — United States, June 1–July 25, 2020.
Morb. Mortal. Wkly. Rep. 69, 1535 (2020).
39. J. Lessler, A. S. Azman, H. S. McKay, S. M. Moore, What is a Hotspot 519 Vulnerability and a County of County of County of County 19 Hotspot 20

139. J. Lessler, A. S. Azman, H. S. McKay, S. M. Moore, What is a Hotspot Anyway? Am. J. Trop. Med. Hyg. 96,

1270 (2017).

40. L. M. Andersen, S. R. 21 39. J. Lessler, A. S. Azman, H. S. McKay, S. M. Moore, What is a Hotspot Anyway? Am. J. Trop. Med. Hyg. **96**, 1270 (2017).
1270 (2017).
40. L. M. Andersen, S. R. Harden, M. M. Sugg, J. D. Runkle, T. E. Lundquist, Analyzing 22 523 determinants of local Covid-19 transmission in the United States. *Sci. Total Environ.* **754**, 142396 (2021).
41. H. Kim, A. Zanobetti, M. L. Bell, Temporal transition of racial/ethnic disparities in COVID-19 outcomes determinants of local Covid-19 transmission in the United States. Sci. Total Environ. 754, 142396 (2021). 24 determinants of local Covid-19 transmission in the Onted States. Sci. Total Environ. 754, 142396 (2021).
41. H. Kim, A. Zanobetti, M. L. Bell, Temporal transition of racial/ethnic disparities in COVID-19 outco
3108 countie 525 41. H. Kim, A. Zanobetti, M. L. Bell, Three phases from January to December 2020. *Sci. Total Environ*. **791**, 148167 (2021).
148167 (2021).
42. A. R. Maroko, D. Nash, B. T. Pavilonis, COVID-19 and Inequity: a Comparative 526 3108 counties of the United States: Three phases from January to Becember 2020. Sci. Total Environ. 191,
148167 (2021).
York City and Chicago Hot Spots. *J. Urban Health Bull. N. Y. Acad. Med.* 97, 461–470 (2020). 27 148167 (2021).
42. A. R. Maroko, D. Nash, B. T. Pavilonis, COVID-19 and Inequity: a Comparative Spatial Analysis of New
1978 York City and Chicago Hot Spots. J. Urban Health Bull. N. Y. Acad. Med. **97**, 461–470 (2020).
198 528 York City and Chicago Hot Spots. *J. Urban Health Bull. N. Y. Acad. Med.* **97**, 461–470 (2020).
43. L. C. Zalla, C. L. Martin, J. K. Edwards, D. R. Gartner, G. A. Noppert, A Geography of Risk: Structural
Racism and Coronav 529 York City and Cincago Hot Spots. J. Orban Health Bull. N. Y. Acad. Med. 31, 461–470 (2020).
43. L. C. Zalla, C. L. Martin, J. K. Edwards, D. R. Gartner, G. A. Noppert, A Geography
Racism and Coronavirus Disease 2019 Mortal 530 44. C. McAloon, A. Collins, K. Hunt, A. Barber, A. W. Byrne, F. Butler, M. Casey, J. Griffin, E. Lane, D. McEvoy,
44. C. McAloon, Á. Collins, K. Hunt, A. Barber, A. W. Byrne, F. Butler, M. Casey, J. Griffin, E. Lane, D. Mc 531 Racism and Coronavirus Disease 2019 Mortality in the United States. Am. J. Epidemiol. 190, 1439–1440 (2021).
44. C. McAloon, Á. Collins, K. Hunt, A. Barber, A. W. Byrne, F. Butler, M. Casey, J. Griffin, E. Lane, D. McEvoy, 532 P. Wall, M. Green, L. O'Grady, S. J. More, Incubation period of COVID-19: a rapid systematic review and meta-
analysis of observational research. *BMJ Open*. **10**, e039652 (2020).
45. A. Cori, N. M. Ferguson, C. Frase 533 534 analysis of observational research. *BMJ Open.* 10, e039632 (2020).
45. A. Cori, N. M. Ferguson, C. Fraser, S. Cauchemez, A New F
Varying Reproduction Numbers During Epidemics. Am. J. Epidemiol
46. M. Alene, L. Yismaw, M. 535 536 varying Reproduction numbers During Epidemics. *Am. J. Epidemiol.* 178, 1505–1512 (2013). Varying Reproduction Numbers During Epidemics. Am. J. Epidemiol. 178, 1505–1512 (2015).
46. M. Alene, L. Yismaw, M. A. Assemie, D. B. Ketema, W. Gietaneh, T. Y. Birhan, S
incubation period of COVID-19: a systematic review 537 16. M. Alene, L. Alene, L. Y. Alene, L. Y. Alene, M. Alene, M. Alene, D. 2019.
16. M. Alene, M. Angrist, R. Goldszmidt, B. Kira, A. Petherick, T. Phillips, S. Webster, E. Cameron-Blake, L.
16. Hallas, S. Majumdar, H. Tatlo incubation period of COVID-19: a systematic review and meta-analysis. *BMC Infect. Dis.* 21, 1–9 (2021).
47. T. Hale, N. Angrist, R. Goldszmidt, B. Kira, A. Petherick, T. Phillips, S. Webster, E. Cameron-I 538 incubation period of COVID-19: a systematic review and meta-analysis. BMC infect. Dis. 21, 1–9 (2021).
47. T. Hale, N. Angrist, R. Goldszmidt, B. Kira, A. Petherick, T. Phillips, S. Webster, E. Cameron-E
Hallas, S. Majumda 539 Hallas, S. Majumdar, H. Tatlow, A global panel database of pandemic policies (Oxford COVID-19 Government
Response Tracker). *Nat. Hum. Behav. 2021 54*. **5**, 529–538 (2021).
48. COVID-19 Trends and Impact Survey | Delphi Ep 540 541 48. COVID-19 Trends and Impact Survey | Delphi Epidata API,
delphi.github.io/delphi-epidata/symptom-survey/).
49. J. A. Salomon, A. Reinhart, A. Bilinski, E. J. Chua, W. Ia Motte-Kerr, M. 42 543 49. J. A. Salomon, A. Reinhart, A. Bilinski, E. J. C.
Morris, S. LaRocca, T. H. Farag, F. Kreuter, R. Roser
Survey: Continuous real-time measurement of COV J. A. Salomon, A. Reinhart, A. Bilinski, E. J. Chua, W. Ia Motte-Kerr, M. M. Rönn, M. B. Reitsma, K. A. 544 Morris, S. LaRocca, T. H. Farag, F. Kreuter, R. Rosenfeld, R. J. Tibshirani, The US COVID-19 Trends and Impact
Survey: Continuous real-time measurement of COVID-19 symptoms, risks, protective behaviors, testing, and
vaccin 545 Morris, S. LaRocca, T. H. Farag, F. Kreuter, R. Rosenfeld, R. J. Tibshirani, The US COVID-19 Trends and Impact Survey: Continuous real-time measurement of COVID-19 symptoms, risks, protective behaviors, testing, and
vaccination *Proc. Natl. Acad. Sci. U. S. A.* 118 (2021), doi:10.1073/PNAS.2111454118.
50. Google LLC, Google COVID-1 546 vaccination. Proc. Natl. Acad. Sci. U. S. A. 118 (2021), doi:10.1073/PNAS.2111454118.
S0. Google LLC, Google COVID-19 Community Mobility Reports, (available at
https://www.google.com/covid19/mobility/).
51. tsa.gov, TSA ch 547 vaccination. Proc. Natl. Acad. Sci. 0. 3. A. 118 (2021), doi:10.1073/PNAS.2111434116.
50. Google LLC, Google COVID-19 Community Mobility Rep
https://www.google.com/covid19/mobility/).
51. tsa.gov, TSA checkpoint travel num 548 https://www.google.com/covid19/mobility/).
51. tsa.gov, TSA checkpoint travel numbers (current year versus prior year(s)/same weekday) |
Transportation Security Administration, (available at https://www.tsa.gov/coronavirus 549 https://www.google.com/covid-19/mobility-19/mobility-19/mobility-19/mobility-19/mobility-19/mobility-19/mobili
1992 - The Paul, A. M. France, Y. Aoki, D. Batra, 550 Transportation Security Administration, (available at https://www.tsa.gov/coronavirus/passenger-throughput).
52. P. Paul, A. M. France, Y. Aoki, D. Batra, M. Biggerstaff, V. Dugan, S. Galloway, A. J. Hall, M. A. Johansson, 551 Transportation Security Administration, (aramans at https://www.tsa.gov/coronavirus/passenger-intenguput).
Transportation, A. M. France, Y. Aoki, D. Batra, M. Biggerstaff, V. Dugan, S. Galloway, A. J. Hall, M. A. Johansson 552 52. J. Kondor, A. L. Halpin, B. Lee, J. S. Lee, B. Limbago, A. MacNeil, D. MacCannell, C. R. Paden, K. Queen, H. E.
Reese, A. C. Retchless, R. B. Slayton, M. Steele, S. Tong, M. S. Walters, D. E. Wentworth, B. J. Silk, Gen 553 Reese, A. C. Retchless, R. B. Slayton, M. Steele, S. Tong, M. S. Walters, D. E. Wentworth, B. J. Silk, Genomic
Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020–May 2021. MMWR
Morb. Morta 554 Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020–May 2021. MMWR
Morb. Mortal. Wkly. Rep. 70, 846–850 (2021).
53. Global Hourly - Integrated Surface Database (ISD) | National Centers 555 ⁵⁵⁶ Morb. Mortal. Wkly. Rep. 70, 846–850 (2021). Morb. Mortal. Wkly. Rep. **70**, 846–850 (2021).
53. Global Hourly - Integrated Surface Database (ISD) | National Centers for Environmental Information
(NCEI), (available at https://www.ncei.noaa.gov/products/land-based-s 557 Solelly, (available at https://www.ncei.noaa.gov/products/land-based-station/integrated-surface-database).
54. D. Carslaw, Import Surface Meteorological Data from NOAA Integrated Surface Database (ISD) •
worldmet (2021), (558 (NCEI), Carslaw, Import Surface Meteorological Data from NOAA Integrated Surface Database (ISD)
worldmet (2021), (available at https://davidcarslaw.github.io/worldmet/). 559 worldmet (2021), (available at https://davidcarslaw.github.io/worldmet/). 560 where $\frac{1}{2}$ and $\frac{1}{2}$ are https://david.io/worldmet/).

- 55.
- Influenza in the Continental US. *PLoS Curr.* **2** (2009), doi:10.1371/CURRENTS.RRN1138.
56. Y. Ma, S. Pei, J. Shaman, R. Dubrow, K. Chen, Role of meteorological factors in the transmission of SARS-
CoV-2 in the United St Influenza in the Continental US. Plos Curr. 2 (2005), doi:10.1571/CORRENTS.RRN1138.
56. N. Ma, S. Pei, J. Shaman, R. Dubrow, K. Chen, Role of meteorological factors in th
CoV-2 in the United States. Nat. Commun. 2021 121.
- Lessier, H. Saije, A. T. Huang, D. A. T. Cummings, Accounting for assay performance when estimating the Cov-2 in the Officer States. Nat. Commun. 2021 121. 12, 1–9 (2021).
57. B. García-Carreras, M. D. T. Hitchings, M. A. Johansson, M.
Lessler, H. Salje, A. T. Huang, D. A. T. Cummings, Accounting for
temporal dynamics in SAR 565 Lessler, H. Salje, A. T. Huang, D. A. T Cummings, Accounting for assay performance when estimating the
temporal dynamics in SARS-CoV-2 seroprevalence in the U.S, doi:10.1101/2022.09.13.22279702.
58. COVID-19 Vaccination Tr 566 67
- temporal dynamics in SARS-CoV-2 seroprevalence in the U.S, doi:10.1101/2022.09.13.22279702.
58. COVID-19 Vaccination Trends in the United States,National and Jurisdictional | Data | Centers for
Disease Control temporal dynamics in Temporal diversions in the United States, National and Jurisdictional | Data
Disease Control and Prevention, (available at https://data.cdc.gov/Vaccinations/COVID-19-Vaccin
in-the-United-States-N/rh2h-568 58. Control and Prevention, (available at https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-Trends-
in-the-United-States-N/rh2h-3yt2).
59. P. Smittenaar, N. Stewart, S. Sutermaster, L. Coome, A. Dibner-Dunlap, M. Jain 569 570
- S. K. Sgaler, *medKxiv*, in press, doi:10.1101/2021.05.19.21257455. 59. P. Smittenaar, N. Stewart, S. :
S. K. Sgaier, *medRxiv*, in press, doi:1
60. A. Vehtari, A. Gelman, J. Gabı 571 572
- 59. P. Smittenaar, N. Stewart, S. Sutermaster, L. Coome, A. Dibner-Dunlap, M. Jain, Y. Caplan, C. Campigotto,
S. K. Sgaier, *medRxiv*, in press, doi:10.1101/2021.05.19.21257455.
60. A. Vehtari, A. Gelman, J. Gabry, Practic 573 574
- S. Abbott, J. Hellewell, R. N. Thompson, K. Sherratt, H. P. Gibbs, N. I. Bosse, J. D. Munday, S. Meakin, E. L. and WAIC, *Stat. Comput. 2016 275*. 27, 1413–1432 (2016).
61. A. S. Abbott, J. Hellewell, R. N. Thompson, K. Sherratt, H. P. Gibbs, N. I. Bosse, J. D. Munday, S. Meakin, E. L
Doughty, J. Y. Chun, Y.-W. D. Chan, F. Finger, and WAIC. Stat. Comput. 2010 275. 27, 1415–1432 (2010).
61. S. Abbott, J. Hellewell, R. N. Thompson, K. Sherratt, I
Doughty, J. Y. Chun, Y.-W. D. Chan, F. Finger, P. Campbell
Covid, S. Flasche, A. J. Kucharski, R. M. Eggo, 575 Doughty, J. Y. Chun, Y.-W. D. Chan, F. Finger, P. Campbell, A. Endo, C. A. B. Pearson, A. Gimma, T. Russell, C.
Covid, S. Flasche, A. J. Kucharski, R. M. Eggo, S. Funk, F. Chirico, C. Althaus, Estimating the time-varying
r 576 Covid, S. Flasche, A. J. Kucharski, R. M. Eggo, S. Funk, F. Chirico, C. Althaus, Estimating the time-varying
reproduction number of SARS-CoV-2 using national and subnational case counts. Wellcome Open Res. 2020
5112. 5, 11 577 Covid, S. Franch, A. J. M. J. Martin, A. M. Eggo, S. Franch, F. Chirico, C. Althaus, Estimating the time-varying
Reproduction number of SARS-CoV-2 using national and subnational case counts. Wellcome Open Res. 2020
5112. 5 578 reproduction number of SARS-CoV-2 using national and subnational case counts. Wellcome Open Res. 2020
5112. 5, 112 (2020).
dgments

$\frac{80}{21}$ As Figure 2.1 81 **Acknowledgments**

5112. 5, 112 (2020).

579 5112. 5, 112 (2020).

81 **Acknowledgments**

82 This research is based on survey results from Carnegie Mellon University's Delphi Group. Thank you to Prabasaj Paul for

83 his thoughtful comments a 582 This thoughtful comments and review of this manuscript.
 Funding: None. 583 his thoughtful comments and review of this manuscript.
Funding: None.

84
85 Funding: None.

⁵⁹⁷

61

562

563

564

- 86
87
- 85 **Funding: None.**
86
87 **Author contribu**
88 **Concept** 88
- 87 Author contributions:

88 Conceptualizat

89 Methodology:

90 Investigation: \ Conceptualization: VKL, MAJ
Methodology: VKL, MAJ, SK, JMH
Investigation: VKL, SK, PVP, TC
Visualization: VKL
Supervision: MAJ, RSB, MB 589
- Investigation: VKL, SK, PVP, TC 590
- 91
- Supervision: MAJ,
Writing—original ‹
Writing—review 8 592
- Visualization: VKL
Supervision: VKL
Writing—original draft: VKL Vriting—original draft: VKL
Writing—review & editing: 593
- 94
- Writing—review & editing: V
Competing interests: All other autho Competing interests: All other authors declare they have no competing interest 95
96

available in a public repository (https://github.com/cdcepi/COVID-19-Mitigation_Rt).

596 Data and materials availability: All data are available in the main text or the supplementary materials. COVID-19 case
596 data are available upon request at https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveil data are available upon request at https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Restricted-99 600 available in a public repository (https://github.com/cdcepi/COVID-19-Mitigation Rt). 01

12 Figures

$\overline{3}$ $\mathsf{I}4$

605

16

17

608

 implementation of specific non-pharmaceutical interventions (NPIs). State-wide implementation of stay-at-home orders are in red, restrictions on gatherings in yellow, cancellation of public events in dark blue, and universal masking when physical distancing was not possible in light blue. The solid vertical line represents January 1, 2021 and the dashed horizontal line reflects an Rt value of 1.0.

 $\overline{0}$ variants in circulation, weather, and immunity to SARS-CoV-2. Lines reflect jurisdiction-level observations over time, with the median values across jurisdictions 612depicted by the bold line. The solid, black vertical line represents January 1, 2021. B. Average of the three selected Community Covid-19 Vulnerability Index 613(CCVI) indicators for each jurisdiction.

616 **Figure 3**. Percent change in the COVID-19 time-varying reproduction (R_t) number from policies, personal 617 COVID-19 behaviors, proportion of key SARS-CoV-2 variants in circulation, weather, immunity to SARS-

617 COVID-19 behaviors, proportion of key SARS-CoV-2 variants in circulation, weather, immunity to SARS-
618 CoV-2, and variables affecting underlying trends in transmission. The results from two different linear 618 CoV-2, and variables affecting underlying trends in transmission. The results from two different linear
619 Fregression models are shown below. Model one, in pink, included the Oxford Stringency Index (OSI). 619 regression models are shown below. Model one, in pink, included the Oxford Stringency Index (OSI).
620 Model two, in purple, included a subset of policies used to comprise the OSI. Both regression models 620 Model two, in purple, included a subset of policies used to comprise the OSI. Both regression models
621 were gaussian with log link function and had jurisdiction and time specific intercepts. were gaussian with log link function and had jurisdiction and time specific intercepts.

24 Figure 4. Estimates for jurisdiction-level proportional reductions in the COVID-19 time-varying reproduction number (R_t) over time for the Oxford Stringency

Index (OSI) regression model. Colored lines depict the relative reduction for select sets of covariates and the solid vertical line represents January 1, 2021.

625626

628 **Figure 5**. Average relative contribution of observed covariates on fitted COVID-19 time-varying
629 reproduction number (R_t) across all jurisdictions from the OSI model. The highest values over time (i.e., 629 reproduction number (R_t) across all jurisdictions from the OSI model. The highest values over time (i.e., 530 the top of the pink band) represent R_t estimates including only the effects of local vulnerability and 530 the top of the pink band) represent R_t estimates including only the effects of local vulnerability and 531 variants. The pink bands sequents reductions in Rt associated with changing weather. The blue bands 631 variants. The pink band represents reductions in Rt associated with changing weather. The blue bands 532 represent reductions in R_t associated with infection-acquired immunity (dark blue) and with behavior for the sepresent reductions in R_t associated with infection-acquired immunity (dark blue) and with behavior
for a modification (i.e., masking use, mobility, and national airline travel, combined and depicted with light 633 modification (i.e., masking use, mobility, and national airline travel, combined and depicted with light 534 blue). The green bands represent reductions in R_t associated with policies (light green) and vaccination 534 blue). The green bands represent reductions in R_t associated with policies (light green) and vaccination
535 (dark green). The fitted values from the regression model are represented with the top of the black band. 635 (dark green). The fitted values from the regression model are represented with the top of the black band.
636 The solid vertical line represents January 1, 2021. The solid vertical line represents January 1, 2021.

